FONAR (FONR) 10-K 13 Oct 21 2021 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Jun. 30, 2021	Sep. 15, 2021	Dec. 31, 2020
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--06-30
Entity File Number	0-10248
Entity Registrant Name	FONAR CORPORATION
Entity Central Index Key	0000355019
Entity Tax Identification Number	11-2464137
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	110 Marcus Drive
Entity Address, City or Town	Melville
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	11747
City Area Code	(631)
Local Phone Number	694-2929
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 110,000,000
Common Stock [Member]
Entity Common Stock, Shares Outstanding		6,554,210
Common Class B [Member]
Entity Common Stock, Shares Outstanding		146
Common Class C [Member]
Entity Common Stock, Shares Outstanding		382,513
Class A Non Voting Preferred Stock [Member]
Entity Common Stock, Shares Outstanding		313,438

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Current Assets:
Cash and cash equivalents	$ 44,460,411	$ 36,802,342
Short term investments	32,177	31,884
Accounts receivable – net of allowances for doubtful accounts of $442,270 and $514,561 at June 30, 2021 and 2020, respectively	4,525,435	4,312,999
Accounts receivable – related party	11,977	5,988
Medical receivables - net	17,900,489	16,171,782
Management and other fees receivable – net of allowances for doubtful accounts of $15,786,878 and $11,063,233 at June 30, 2021 and 2020, respectively	30,947,863	27,437,768
Management and other fees receivable – related party medical practices – net of allowances for doubtful accounts of $4,184,399 and $3,322,055 at June 30, 2021 and 2020, respectively	7,814,250	6,896,482
Contract assets		152,833
Inventories	1,663,419	1,648,770
Income tax receivable		671,185
Prepaid expenses and other current assets	1,227,463	1,757,499
Total Current Assets	108,583,484	95,889,532
Accounts receivable – long term	2,879,946	2,730,071
Deferred income tax asset	15,958,961	18,809,757
Property and equipment – net	21,850,139	21,364,034
Right-of-use-asset – operating leases	30,133,285	31,392,458
Right-of-use-asset – financing lease	1,126,990	1,325,870
Goodwill	4,269,277	3,985,397
Other intangible assets – net	4,037,599	4,109,129
Other assets	666,514	653,132
Total Assets	189,506,195	180,259,380
Current Liabilities:
Current portion of long-term debt and capital leases	173,206	108,379
Accounts payable	1,866,035	1,965,259
Other current liabilities	9,162,118	8,185,098
Operating lease liability – current portion	3,533,656	3,370,149
Financing lease liability – current portion	202,741	74,699
Unearned revenue on service contracts	4,365,825	4,105,265
Customer deposits	731,101	854,579
Contract liabilities	14,739
Total Current Liabilities	20,049,421	18,663,428
Long-Term Liabilities:
Unearned revenue on service contracts	2,800,522	2,655,605
Deferred income tax liability	238,316	234,106
Due to related party medical practices	92,663	92,663
Operating lease liability – net of current portion	28,975,132	30,104,464
Financing lease liability – net of current portion	1,048,431	1,251,171
Long-term debt and capital leases, less current portion	760,254	865,416
Other liabilities	171,331	150,311
Total Long-Term Liabilities	34,086,649	35,353,736
Total Liabilities	54,136,070	54,017,164
Stockholders’ Equity:
Paid-in capital in excess of par value	185,100,976	183,076,888
Accumulated deficit	(46,007,663)	(56,215,251)
Treasury stock, at cost – 11,643 shares of common stock at June 30, 2021 and 2020	(675,390)	(675,390)
Total Fonar Corporation’s Stockholders’ Equity	138,418,649	126,186,963
Noncontrolling interests	(3,048,524)	55,253
Total Stockholders’ Equity	135,370,125	126,242,216
Total Liabilities and Stockholders’ Equity	189,506,195	180,259,380
Class A Non Voting Preferred Stock [Member]
Stockholders’ Equity:
Preferred Stock Value	31	31
Preferred Stock [Member]
Stockholders’ Equity:
Preferred Stock Value
Common Stock [Member]
Stockholders’ Equity:
Common Stock Value	657	647
Common Class B [Member]
Stockholders’ Equity:
Common Stock Value
Common Class C [Member]
Stockholders’ Equity:
Common Stock Value	$ 38	$ 38

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2021	Jun. 30, 2020
Class A Non Voting Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share		$ 0.0001
Preferred Stock, Shares Authorized		453,000
Preferred Stock, Shares Outstanding		313,438
Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share		$ 0.001
Preferred Stock, Shares Authorized		567,000
Preferred Stock, Shares Outstanding		0
Common Stock [Member]
Common Stock, Par or Stated Value Per Share		$ 0.0001
Common Stock, Shares Authorized		8,500,000
Common Stock, Shares, Issued	6,565,853	6,459,106
Common Stock, Shares, Outstanding	6,554,210	6,447,463
Common Class B [Member]
Common Stock, Par or Stated Value Per Share		$ 0.0001
Common Stock, Shares Authorized		227,000
Common Stock, Shares, Outstanding		146
Common Class C [Member]
Common Stock, Par or Stated Value Per Share		$ 0.0001
Common Stock, Shares Authorized		567,000
Common Stock, Shares, Outstanding		382,513

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Revenues
Patient fee revenue, net of contractual allowances and discounts	$ 23,307,389	$ 22,495,260
Product sales – net	1,288,483	297,613
Service and repair fees – net	7,638,608	8,055,490
Service and repair fees – related parties – net	110,000	110,000
Management and other fees – net	46,609,449	44,565,405
Management and other fees – related party medical practices – net	10,975,836	10,166,694
Total Revenues – Net	89,929,765	85,690,462
Costs and Expenses
Costs related to product sales	1,032,676	745,375
Costs related to service and repair fees	2,740,625	2,731,397
Costs related to service and repair fees – related parties	39,466	37,298
Costs related to patient fee revenue	10,917,635	10,880,265
Costs related to management and other fees	25,384,557	22,951,301
Costs related to management and other fees – related party medical practices	6,341,168	5,951,189
Research and development	1,635,979	2,025,376
Selling, general and administrative, inclusive of compensatory element of stock issuances of $83,277 and $0 for the years ended June 30, 2021 and 2020 respectively	24,740,044	26,717,345
Total Costs and Expenses	72,832,150	72,039,546
Income from Operations	17,097,615	13,650,916
Other Income and (Expenses):
Interest expense	(248,665)	(74,321)
Investment income	311,931	502,145
Other income	504,450	70,771
Income before provision for income taxes and noncontrolling interests	17,665,331	14,149,511
Provision for Income Taxes	(3,991,520)	(2,444,778)
Net Income	13,673,811	11,704,733
Net Income – Noncontrolling Interests	(3,466,223)	(3,464,528)
Net Income - Attributable to FONAR	$ 10,207,588	$ 8,240,205
Weighted Average Basic Shares Outstanding	6,505,283	6,443,713
Common Stock [Member]
Other Income and (Expenses):
Net Income - Attributable to FONAR	$ 9,592,134	$ 7,735,650
Basic Net Income Per Share	$ 1.47	$ 1.20
Diluted Net Income Per Share	$ 1.45	$ 1.18
Weighted Average Basic Shares Outstanding	6,505,283	6,443,713
Weighted Average Basic Shares Outstanding	6,632,787	6,571,217
Preferred Class A [Member]
Other Income and (Expenses):
Net Income - Attributable to FONAR	$ 458,710	$ 376,055
Common Class C [Member]
Other Income and (Expenses):
Net Income - Attributable to FONAR	$ 156,744	$ 128,500
Basic Net Income Per Share	$ 0.41	$ 0.34
Diluted Net Income Per Share	$ 0.41	$ 0.34
Weighted Average Basic Shares Outstanding	382,513	382,513
Weighted Average Basic Shares Outstanding	382,513	382,513
Weighted Average Basic and Diluted Shares Outstanding	382,513	382,513

CONSOLIDATED STATEMENTS OF IN_2

CONSOLIDATED STATEMENTS OF INCOME (Parenthetical) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Stock Issued During Period, Value, Employee Benefit Plan	$ 83,277	$ 0

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Class A Non Voting Preferred [Member]	Common Stock [Member]	Class C Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Noncontrolling Interest [Member]	Total
Beginning balance, value at Jun. 30, 2019	$ 31	$ 638	$ 38	$ 181,086,517	$ (64,455,456)	$ (675,390)	$ 2,155,725	$ 118,112,103
Beginning Balance, Shares at Jun. 30, 2019		6,357,482
Net income					8,240,205		3,464,528	11,704,733
Stock issued to employees under stock bonus plans		$ 9		1,990,371				1,990,380
Stock issued to employees under stock bonus plans, Shares		89,981
Payments on notes receivable from employee stockholders
Distributions to noncontrolling interests							(5,565,000)	(5,565,000)
Ending balance, value at Jun. 30, 2020	31	$ 647	38	183,076,888	(56,215,251)	(675,390)	55,253	126,242,216
Ending Balance, Shares at Jun. 30, 2020		6,447,463
Net income					10,207,588		3,466,223	13,673,811
Stock issued to employees under stock bonus plans		$ 10		2,024,088				2,024,098
Stock issued to employees under stock bonus plans, Shares		106,747
Distributions to noncontrolling interests							(6,570,000)	(6,570,000)
Ending balance, value at Jun. 30, 2021	$ 31	$ 657	$ 38	$ 185,100,976	$ (46,007,663)	$ (675,390)	$ (3,048,524)	$ 135,370,125
Ending Balance, Shares at Jun. 30, 2021		6,554,210

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income	$ 13,673,811	$ 11,704,733
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	4,081,687	3,908,648
Provision for bad debts	5,585,989	5,695,420
Deferred income tax - net	2,855,006	2,118,829
Income tax receivable	671,185	528,815
Amortization on right-of-use assets	1,458,053	1,005,560
Compensatory element of stock issuances	83,277
Stock issued for costs and expenses	1,940,821	1,990,380
Abandoned patents	534
(Increase) decrease in operating assets, net:
Accounts, medical and management fee receivables	(12,110,859)	(10,797,456)
Notes receivable	46,944	28,889
Contract assets	152,833	372,277
Inventories	(14,649)	149,396
Prepaid expenses and other current assets	526,425	(133,287)
Other assets	(18,087)	(161,350)
Increase (decrease) in operating liabilities, net:
Accounts payable	(99,224)	104,032
Other current liabilities	1,382,497	3,556,437
Customer advances	(123,478)	55,928
Operating lease liabilities	(965,825)	159,657
Financing lease liabilities	(74,698)
Contract liabilities	14,739
Other liabilities	21,020	115,855
NET CASH PROVIDED BY OPERATING ACTIVITIES	19,088,001	20,402,763
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(3,533,091)	(7,522,997)
Proceeds of Short term investment	(293)	15,062,932
Purchase of imaging center	(1,122,508)
Cost of patents	(163,705)	(117,522)
NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES	(4,819,597)	7,422,413
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of borrowings and capital lease obligations	(103,335)	(4,957,936)
Proceeds from debt	63,000	5,618,089
Distributions to noncontrolling interests	(6,570,000)	(5,565,000)
NET CASH USED IN FINANCING ACTIVITIES	(6,610,335)	(4,904,847)
NET INCREASE IN CASH AND CASH EQUIVALENTS	7,658,069	22,920,329
CASH AND CASH EQUIVALENTS – BEGINNING OF YEAR	36,802,342	13,882,013
CASH AND CASH EQUIVALENTS – END OF YEAR	$ 44,460,411	$ 36,802,342

NOTE 1 - DESCRIPTION OF BUSINES

NOTE 1 - DESCRIPTION OF BUSINESS AND LIQUIDITY AND CAPITAL RESOURCES	12 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
NOTE 1 - DESCRIPTION OF BUSINESS AND LIQUIDITY AND CAPITAL RESOURCES	NOTE 1 - DESCRIPTION OF BUSINESS AND LIQUIDITY AND CAPITAL RESOURCES Description of Business FONAR Corporation (the “Company” or “FONAR”) is a Delaware corporation, which was incorporated on July 17, 1978. FONAR is engaged in the research, development, production and marketing of medical scanning equipment, which uses principles of Magnetic Resonance Imaging (“MRI”) for the detection and diagnosis of human diseases. In addition to deriving revenues from the direct sale of MRI equipment, revenue is also generated from our installed-base of customers through our service and upgrade programs. FONAR, through its wholly-owned subsidiary Health Management Corporation of America (“HMCA”) provides comprehensive management services to diagnostic imaging facilities. The services provided by the Company include development, administration, leasing of office space, facilities and medical equipment, provision of supplies, staffing and supervision of non-medical personnel, legal services, accounting, billing and collection and the development and implementation of practice growth and marketing strategies. On July 1, 2015, the Company restructured the corporate organization of the management of diagnostic imaging centers segment of our business. The reorganization was structured to more completely integrate the operations of Health Management Corporation of America and HDM. Imperial contributed all of its assets (which were utilized in the business of Health Management Corporation of America) to HDM and received a 24.2 % interest in HDM. Health Management Corporation of America retained a direct ownership interest of 45.8 % in HDM, and the original investors in HDM retained a 30.0 % ownership interest in the newly expanded HDM. The entire management of diagnostic imaging centers business segment is now being conducted by HDM. During March 2020 the global pandemic of COVID-19 has caused turbulence and uncertainty in the United States and international markets and economies which has adversely effected our workforce, liquidity, financial conditions, revenues, profitability and business operations. Generally COVID-19 had caused us to require that much of our workforce work from home and has restricted the ability of our personnel to travel for marketing purposes or to service our customers. The Company experienced a sudden drop in scan volume for a short term period and the Company has been steadily recovering to pre-COVID-19 levels. At the end of fiscal year ending June 30, 2020, the Company was able to enact certain decisions to allow the Company to survive during the global pandemic and from further losses or additional decreases in scan volume. The Company also received some government stimulus funds from the Paycheck Protection Program (‘PPP’) program and Medicare advances/stimulus payments. Although we are unable to predict if there will be additional consequences on our operations from the continuing global pandemic of COVID-19 and the new variants, the Company believes with the positive cash flows, low debt and cash on hand, it will be able to continue operations going forward.

NOTE 2 - SUMMARY OF SIGNIFICANT

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation The consolidated financial statements include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries and partnerships. The operating activities of subsidiaries are included in the accompanying consolidated statements from the date of acquisition. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The most significant estimates relate to receivable allowances, intangible assets, income taxes and related tax asset valuation allowances, useful lives of property and equipment, contingencies, revenue recognition and the assessment of litigation. In addition, healthcare industry reforms and reimbursement practices will continue to impact the Company’s operations and the determination of contractual and other allowance estimates. Actual results could differ from those estimates. Inventories Inventories consist of purchased parts, components and supplies, as well as work-in-process, and are stated at the lower of cost, determined on the first-in, first-out method, or market. Property and Equipment Property and equipment procured in the normal course of business is stated at cost. Property and equipment purchased in connection with an acquisition is stated at its estimated fair value, generally based on an appraisal. Property and equipment is being depreciated for financial accounting purposes using the straight-line method over their estimated useful lives. Leasehold improvements are being amortized over the shorter of the useful life or the remaining lease term. Upon retirement or other disposition of these assets, the cost and related accumulated depreciation of these assets are removed from the accounts and the resulting gains or losses are reflected in the results of operations. Expenses for maintenance and repairs are charged to operations. Renewals and betterments are capitalized. Maintenance and repair expenses totaled approximately $ 2,051,000 and $ 1,870,000 for the years ended June 30, 2021 and 2020 respectively. The estimated useful lives in years are generally as follows: Estimated Useful Life in Years for Property and Equipment Diagnostic equipment 5 – 13 Research, development and demonstration equipment 3 - 7 Machinery and equipment 2 - 7 Furniture and fixtures 3 - 9 Leasehold improvements 3 – 10 Building 28 Long-Lived Assets The Company periodically assesses the recoverability of long-lived assets, including property and equipment and intangibles, other than goodwill, when there are indications of potential impairment, based on estimates of undiscounted future cash flows. The amount of impairment is calculated by comparing anticipated discounted future cash flows with the carrying value of the related asset. In performing this analysis, management considers such factors as current results, trends, and future prospects, in addition to other economic factors. Other Intangible Assets 1) Patents and Copyrights Amortization is calculated on the straight-line basis over 15 years. 2) Non-Competition Agreements The non-competition agreements are being amortized on the straight line basis over the length of the agreement ( 7 years). 3) Customer Relationships Amortization is calculated on the straight line basis over 20 years. Goodwill Generally accepted accounting principles in the United States require the Company to perform a goodwill impairment test annually and more frequently when negative conditions or a triggering event arises. Impairment of goodwill is tested at the reporting unit level by comparing the reporting unit’s carrying amount, including goodwill to the fair value of the reporting unit. If the carrying amount of the reporting unit exceeds its fair value, goodwill is considered potentially impaired and a second step is performed to measure the amount of impairment loss, if any. Acquired assets and assumed liabilities Pursuant to ASC No. 805-10-25, if the initial accounting for a business combination is incomplete by the end of the reporting period in which the combination occurs, but during the allowed measurement period not to exceed one year from the acquisition date, the Company adjusts the provisional amounts recognized at the acquisition date by means of adjusting the amount recognized for goodwill. Revenue Recognition Revenue on sales contracts for scanners, included in “product sales” in the accompanying consolidated statements of operations, is recognized under the percentage-of-completion method in accordance with FASB ASC 606, “Revenue Recognition – Construction-Type and Production-Type Contracts”. The Company manufactures its scanners under specific contracts that provide for progress payments. Production and installation take approximately three to six months. Revenue on scanner service contracts is recognized on the straight-line method over the related contract period, usually one year. Revenue from product sales (upgrades and supplies) is recognized upon shipment. Revenue under management contracts is recognized based upon contractual agreements for management services rendered by the Company primarily under various long-term agreements with various medical providers (the “PCs”). As of June 30, 2021, the Company has twenty two 22 management agreements of which three 3 are with PC’s owned by Raymond V. Damadian, M.D., Chairman of the Board of FONAR (“the Related medical practices”) and nineteen 19 are with PC’s, which are all located in the state of New York (“the New York PC’s”), owned by two unrelated radiologists. The contractual fees for services rendered to the PCs consists of fixed monthly fees per diagnostic imaging facility ranging from approximately $ 77,000 to $ 522,000 . All fees are re-negotiable at the anniversary of the agreements and each year thereafter. The Company records a provision for bad debts for estimated uncollectible fees, which is reflected in other operating expenses on the Statement of Operations. All fees are re-negotiable at the anniversary of the agreements and each year thereafter. On July 1, 2018, the Company adopted the new revenue recognition accounting standard issued by the Financial Accounting Standards Board (“FASB”) and codified in the ASC as topic 606 (“ASC 606”). The revenue recognition standard in ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires expanded disclosures regarding the Company’s revenue recognition policies and significant judgments employed in the determination of revenue. The Company applied the modified retrospective approach to all contracts when adopting ASC 606. As a result, at the adoption of ASC 606 the majority of what was previously classified as the provision for bad debts in the statement of operations is now reflected as implicit price concessions (as defined in ASC 606) and therefore included as a reduction to net operating revenues in 2019. For changes in credit issues not assessed at the date of service, the Company will prospectively recognize those amounts in other operating expenses on the statement of operations. For periods prior to the adoption of ASC 606, the provision for bad debts has been presented consistent with the previous revenue recognition standards that required it to be presented separately as a component of net operating revenues. Our revenues generally relate to net patient fees received from various payers and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. The Company’s patient fee revenues, net of contractual allowances and discounts less the provision for bad debts for the years ended June 30, 2021 and 2020 are summarized in the following table. Patient Fee Revenue - Net For the Years Ended June 30 2021 2020 Commercial Insurance/ Managed Care $ 4,100,440 $ 4,545,987 Medicare/Medicaid 968,055 1,038,288 Workers’ Compensation/Personal Injury 15,011,111 16,028,737 Other 3,227,783 882,248 Net Patient Fee Revenue $ 23,307,389 $ 22,495,260 Research and Development Costs Research and development costs are charged to expense as incurred. The costs of equipment that are acquired or constructed for research and development activities, and have alternative future uses (either in research and development, marketing or production), are classified as property and equipment and depreciated over their estimated useful lives. Advertising Costs Advertising costs are expensed as incurred. Advertising expense approximated $ 633,000 and $ 566,000 and for the years ended June 30, 2021 and 2020, respectively. Shipping Costs The Company’s shipping and handling costs are included in revenue from product sales and the related expense included in costs related to product sales is $ 8,215 and $ 12,056 for the years ended June 30, 2021 and 2020 respectively. Income Taxes Deferred tax assets and liabilities are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Customer Advances Cash advances and progress payments received on sales orders are reflected as customer advances until such time as revenue recognition occurs. Earnings Per Share Basic earnings per share (“EPS”) is computed by dividing net income available to common stockholders by the weighted average number of shares of common stock outstanding during the period. In accordance with ASC topic 260-10, “Participating Securities and the Two-Class Method”, the Company used the Two-Class method for calculating basic earnings per share and applied the if converted method in calculating diluted earnings per share for the years ended June 30, 2021 and 2020. Diluted EPS reflects the potential dilution from the exercise or conversion of all dilutive securities into common stock based on the average market price of common shares outstanding during the period. For the years ended June 30, 2021 and 2020, diluted EPS for common shareholders includes 127,504 shares upon conversion of Class C Common. Earnings Per Share June 30, 2021 Basic Total Common Stock Class C Common Stock Numerator: Net income available to common stockholders $ 10,207,588 $ 9,592,134 $ 156,744 Denominator: Weighted average shares outstanding 6,505,283 6,505,283 382,513 Basic income per common share $ 1.57 $ 1.47 $ 0.41 Diluted Denominator: Weighted average shares outstanding 6,505,283 382,513 Class C Common Stock 127,504 — Total Denominator for diluted earnings per share 6,632,787 382,513 Diluted income per common share $ 1.45 $ 0.41 June 30, 2020 Basic Total Common Stock Class C Common Stock Numerator: Net income available to common stockholders $ 8,240,205 $ 7,735,650 $ 128,500 Denominator: Weighted average shares outstanding 6,443,713 6,443,713 382,513 Basic income per common share $ 1.28 $ 1.20 $ 0.34 Diluted Denominator: Weighted average shares outstanding 6,443,713 382,513 Class C Common Stock 127,504 — Total Denominator for diluted earnings per share 6,571,217 382,513 Diluted income per common share $ 1.18 $ 0.34 Cash and Cash Equivalents Cash and cash equivalents includes cash on hand, cash in banks, investments in certificates of deposit with original maturities of 90 days or less, and money market funds. Short Term Investments Short term investments include certificates of deposit with original maturities of greater than 90 days. Concentration of Credit Risk Cash: The Company maintains its cash and cash equivalents with various financial institutions, which exceed federally insured limits throughout the year. At June 30, 2021, the Company had cash on deposit of approximately $ 42,609,000 in excess of federally insured limits of $ 250,000 . Related Parties: Net revenues from related parties accounted for approximately 12 % and 12 % of the consolidated net revenues for the years ended June 30, 2021 and 2020, respectively. Net management fee receivables from the related party medical practices accounted for approximately 13 % and 13 % of the consolidated accounts receivable for the years ended June 30, 2021 and 2020, respectively. See Note 3 regarding the Company’s concentrations in the healthcare industry. Fair Value of Financial Instruments The financial statements include various estimated fair value information at June 30, 2021 and 2020, as required by ASC topic 820, “Disclosures about Fair Value of Financial Instruments”. Such information, which pertains to the Company’s financial instruments, is based on the requirements set forth in that Statement and does not purport to represent the aggregate net fair value to the Company. The Company has established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring and revaluing fair value. These tiers include, Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The following methods and assumptions were used to estimate the fair value of each class of financial instruments for which it is practicable to estimate that value: Cash and cash equivalents: The carrying amount approximates fair value because of the short-term maturity of those instruments. Short term investments: The carrying amount approximates fair value because of the short-term maturity of those instruments. Such amounts include Certificates of Deposits with original maturities greater than 90 days. These securities are classified as Level 1. Receivable and accounts payable: The carrying amounts approximate fair value because of the short maturity of those instruments. Notes receivable: The carrying amount approximates fair value because the discounted present value of the cash flow generated by the parties approximates the carrying value of the amounts due to the Company. Long-term debt and notes payable: The carrying amounts of debt and notes payable approximate fair value due to the length of the maturities, the interest rates being tied to market indices and/or due to the interest rates not being significantly different from the current market rates available to the Company. All of the Company’s financial instruments are held for purposes other than trading. Recent Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12 (“ASU 2019-12”), Income Taxes (Topic 740). ASU 2019-12 removes certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other areas of the standard. ASU 2019-12 was effective beginning in the first quarter of 2021. Certain amendments in this update must be applied on a prospective basis, certain amendments must be applied on a retrospective basis, and certain amendments must be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings/(deficit) in the period of adoption. The adoption of this update did not have a material impact on our financial statements. In January 2017, the FASB issued Accounting Standards Update (“ASU”) 2017-04, Intangibles – Goodwill and Other (Topic 350). The amendments in this update simplify the test for goodwill impairment by eliminating Step 2 from the impairment test, which required the entity to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining fair value of assets acquired and liabilities assumed in a business combination. The amendments in this update are effective for public companies for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company adopted the Standard on July 1, 2020 and the impact of adopting this guidance had no material impact on our Consolidated Financial Statements. FASB, the Emerging Issues Task Force and the SEC have issued certain other accounting standards, updates, and regulations as of June 30, 2021 that will become effective in subsequent periods; however, management does not believe that any of those updates would have significantly affected our financial accounting measures or disclosures had they been in effect during 2021 or 2020, and it does not believe that any of those pronouncements will have a significant impact on our consolidated financial statements at the time they become effective.

NOTE 3 _ ACCOUNTS RECEIVABLE, M

NOTE 3 – ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE	12 Months Ended
	Jun. 30, 2021
Receivables [Abstract]
NOTE 3 – ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE	NOTE 3 – ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE Accounts Receivable Credit risk with respect to the Company’s accounts receivable related to product sales and service and repair fees is limited due to the customer advances received prior to the commencement of work performed and the billing of amounts to customers as sub-assemblies are completed. Service and repair fees are billed on a monthly or quarterly basis and the Company does not continue providing these services if accounts receivable become past due. The Company controls credit risk with respect to accounts receivable from service and repair fees through its credit evaluation process, credit limits, monitoring procedures and reasonably short collection terms. The Company performs ongoing credit authorizations before a product sales contract is entered into or service and repair fees are provided. Long Term Accounts Receivable The Company will generate revenue from long-term, non-cancellable contracts to provide service and repair services. Future revenue to be recognized over the following four years at June 30, 2021 is as follows: Receivables - Non Current - net 2023 $ 1,020,140 2024 1,020,140 2025 599,545 2026 160,697 Total $ 2,800,522 Medical Receivable Medical receivables are due under fee-for-service contracts from third party payors, such as hospitals, government sponsored healthcare programs, patient’s legal counsel and directly from patients. Substantially all the revenue relates to patients residing in Florida. The carrying amount of the medical receivable is reduced by an allowance that reflects management’s best estimate of the amounts that will not be collected. The Company determines allowances for contractual adjustments and uncollectible accounts based on specific agings, specific payor collection issues that have been identified and based on payor classifications and historical experience at each site. Management and Other Fees Receivable The Company’s receivables from the related and non-related professional corporations (“PCs”) substantially consist of fees outstanding under management agreements. Payment of the outstanding fees is dependent on collection by the PCs of fees from third party medical reimbursement organizations, principally insurance companies and health management organizations. Payment of the management fee receivables from the PC’s may be impaired by the inability of the PC’s to collect in a timely manner their medical fees from the third party payors, particularly insurance carriers covering automobile no-fault and workers compensation claims due to longer payment cycles and rigorous informational requirements and certain other disallowed claims. Approximately 65 % and 66 %, respectively, of the PCs’ 2021 and 2020 net revenues were derived from no-fault and personal injury protection claims. The Company considers the aging of its accounts receivable in determining the amount of allowance for doubtful accounts. The Company generally takes all legally available steps to collect its receivables. Credit losses associated with the receivables are provided for in the consolidated financial statements and have historically been within management’s expectations. Net revenues from management and other fees charged to the related party medical practices accounted for approximately 12 % and 12 %, of the consolidated net revenues for the years ended June 30, 2021 and 2020, respectively. Tallahassee Magnetic Resonance Imaging, PA, Stand Up MRI of Boca Raton, PA and Stand Up MRI & Diagnostic Center, PA (all related party medical practices) entered into a guaranty agreement, pursuant to which they cross guaranteed all management fees which are payable to the Company, which have arisen under each individual management agreement. The following table sets forth the number of our facilities for the years ended June 30, 2021 and 2020. Total Facilities For the Year Ended June 30, 2021 2020 Total Facilities Owned or Managed (at Beginning of Year) 25 26 Facilities Added by: Acquisition 1 — Internal development 1 — Managed Facilities Closed — (1 ) Total Facilities Owned or Managed (at End of Year) 27 25

NOTE 4 _ CONTRACT ASSETS AND LI

NOTE 4 – CONTRACT ASSETS AND LIABILITIES	12 Months Ended
	Jun. 30, 2021
Regulated Operations [Abstract]
NOTE 4 – CONTRACT ASSETS AND LIABILITIES	NOTE 4 – CONTRACT ASSETS AND LIABILITIES Information relating to uncompleted contracts as of June 30, 2021 and 2020 about contract assets and contract (liabilities) is as follows: `Costs and Estimated Earnings on Uncompleted Contracts As of June 30, 2021 2020 Costs incurred on uncompleted contracts $ 294,783 $ 448,437 Estimated earnings 567,978 309,248 Costs and estimated earnings on uncompleted contracts 862,761 757,685 Less: Billings to date 877,500 604,852 Costs and estimated earnings in excess of billings on uncompleted contracts $ (14,739 ) $ 152,833

NOTE 5 _ INVENTORIES

NOTE 5 – INVENTORIES	12 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
NOTE 5 – INVENTORIES	NOTE 5 – INVENTORIES Inventories included in the accompanying consolidated balance sheets consist of: Inventories As of June 30, 2021 2020 Purchased parts, components and supplies $ 1,393,329 $ 1,544,036 Work-in-process 270,090 104,734 Inventories $ 1,663,419 $ 1,648,770

NOTE 6 - PROPERTY AND EQUIPMENT

NOTE 6 - PROPERTY AND EQUIPMENT	12 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
NOTE 6 - PROPERTY AND EQUIPMENT	NOTE 6 - PROPERTY AND EQUIPMENT Property and equipment, at cost, less accumulated depreciation and amortization, at June 30, 2021 and 2020, is comprised of: Property and Equipment As of June 30, 2021 2020 Diagnostic equipment $ 29,826,829 $ 28,434,063 Research, development and demonstration equipment 6,029,551 5,901,961 Machinery and equipment 2,069,055 2,069,055 Furniture and fixtures 3,450,664 3,291,666 Leasehold improvements 12,961,887 10,736,825 Building 939,614 939,614 55,277,600 51,373,184 Less: Accumulated depreciation and amortization 33,427,461 30,009,150 $ 21,850,139 $ 21,364,034 Depreciation and amortization of property and equipment for the years ended June 30, 2021 and 2020 was $ 3,696,986 and $ 3,144,580 , respectively.

NOTE 7 _ OPERATING & FINANCING

NOTE 7 – OPERATING & FINANCING LEASES	12 Months Ended
	Jun. 30, 2021
Note 7 Operating Financing Leases
NOTE 7 – OPERATING & FINANCING LEASES	NOTE 7 – OPERATING & FINANCING LEASES During February 2016, FAS issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based upon the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Lease with a term of 12 months or less will be accounted for similar to existing guidance for operating leases. The standard was effective for us beginning July 1, 2019. We have elected the optional transition method to apply the standard as of the effective date and therefore, we will not apply the standard to the comparative periods presented in the consolidated financial statements. We have also elected the transition package of thee practical expedients permitted within the standard which eliminates the requirements to reassess prior conclusions about lease identification, lease classification and indirect costs. The adoption of this guidance had a material impact on the Company’s balance sheet by virtue of including the present value of its future operating lease payments as a liability of $ 33.3 million and related right-to-use lease assets as of July 1, 2019. At the time of adoption of this guidance we had no significant financing leases. The Company accounts for its various operating leases in accordance with Accounting Standards Codification (‘ASC’) 842 – Lease, as updated by ASU 2016-02. At the inception of a lease, the Company recognizes right-of-use lease assets and related lease liabilities measured at present value of future lease payments on its balance sheet. Lease expense is recognized on a straight-line basis over the term of the lease. Our most common initial term varies in length from 2 to 10 years. Including renewal options negotiated with the landlord, we have a total span of 2 to 16 years at the facilities we lease. The Company reviewed its contracts with vendors and customers, determining that its right-to-use lease assets consisted of only office space operating leases. In determining the right-to-use lease assets and liabilities, the Company did recognize lease extension options which the Company feels would be reasonably exercised. Our incremental borrowing rate (“IBR”) used to discount the stream of operating lease payments is closely related to the interest rates available to the Company. A reconciliation of operating and financing lease payments undiscounted cash flows to lease liabilities recognized as of June 30, 2021 is as follows: Reconciliation of operating and financing lease payments Year Ending Operating Lease Financing Lease Payments 2022 $ 5,077,656 $ 244,343 2023 5,172,157 244,343 2024 4,837,900 244,343 2025 4,725,550 244,343 2026 4,285,124 244,343 Thereafter 16,950,126 162,898 Present value discount (8,539,725 ) (133,441 ) Total lease liability $ 32,508,788 $ 1,251,172 Weighted Average Remaining Lease Term Operating leases - years 9.4 Finance lease - years 5.6 Weighted Average Discount Rate Operating leases 5.5 % Finance lease 3.6 % The components of lease expense were as follows: Components of lease expense For Year Ended June 30, 2021 June 30, 2020 Operating lease cost $ 6,145,701 $ 5,135,604 Finance lease cost: Depreciation of leased equipment $ 198,881 $ — Interest on lease liabilities 47,472 — Total finance lease cost $ 246,353 $ — Supplemental cash flow information related to leases was as follows: Supplemental cash flow information related to leases For year ended Cash paid for amounts included in the measurement of lease liabilities: June 30, 2021 June 30, 2020 Operating cash flows from operating leases $ 4,970,934 $ 4,170,977 Financing cash flows from financing leases $ 130,038 $ Right-of-use & equipment assets obtained in exchange for lease obligations: Operating leases(1) $ 1,531,889 $ 34,786,611 Financing leases $ — $ 1,325,871 (1) Amounts for the year ended June 30, 2020 include the transition adjustment for the adoption of topic 842 of $31,651,110.

NOTE 8 - OTHER INTANGIBLE ASSET

NOTE 8 - OTHER INTANGIBLE ASSETS	12 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
NOTE 8 - OTHER INTANGIBLE ASSETS	NOTE 8 - OTHER INTANGIBLE ASSETS Other intangible assets, net of accumulated amortization, at June 30, 2021 and 2020 are comprised of: Other Intagible Assets - Net As of June 30, 2021 2020 Capitalized software development costs $ 7,004,847 $ 7,004,847 Patents and copyrights 5,244,892 5,081,721 Non-competition agreements 4,150,000 4,100,000 Customer relationships 3,900,000 3,800,000 20,299,739 19,986,568 Less: Accumulated amortization 16,262,140 15,877,439 $ 4,037,599 $ 4,109,129 The estimated amortization of other intangible assets for the five years ending June 30, 2026 and thereafter is as follows: Schedule Of Other Intangible Assets For the Years Total Patents and Copyrights Non- Customer Relationships 2022 $ 423,209 $ 185,709 $ 37,500 $ 200,000 2023 389,168 189,168 — 200,000 2024 388,867 188,867 — 200,000 2025 383,912 183,912 — 200,000 2026 373,220 173,220 — 200,000 Thereafter 2,079,223 765,056 — 1,314,167 Other intangible assets - net $ 4,037,599 $ 1,685,932 $ 37,500 $ 2,314,167 The weighted average amortization period for other intangible assets is 11.4 years and they have no expected residual value. Information related to the above intangible assets for the years ended June 30, 2021 and 2020 is as follows: Other Intangible Assets As of June 30, 2021 2020 Balance – Beginning of Year $ 4,109,129 $ 4,755,675 Amounts capitalized 313,705 117,522 Software or patents written off (534 ) — Amortization (384,701 ) (764,068 ) Balance – End of Year $ 4,037,599 $ 4,109,129 Amortization of patents and copyrights for the years ended June 30, 2021 and 2020 amounted to $ 179,701 and $ 183,592 , respectively. Capitalized software development costs were fully amortized as of June 30, 2018. Amortization of non-competition agreements for the years ended June 30, 2021 and 2020 amounted to $ 12,500 and $ 390,476 , respectively. Amortization of customer relationships for the years ended June 30, 2021 and 2020 amounted to $ 192,500 and $ 190,000 , respectively.

NOTE 9 - CAPITAL STOCK

NOTE 9 - CAPITAL STOCK	12 Months Ended
	Jun. 30, 2021
Note 9 - Capital Stock
NOTE 9 - CAPITAL STOCK	NOTE 9 - CAPITAL STOCK Common Stock Cash dividends payable on the common stock shall, in all cases, be on a per share basis, one hundred twenty percent (120%) of the cash dividend payable on shares of Class B common stock and three hundred sixty percent (360%) of the cash dividend payable on a share of Class C common stock. Class B Common Stock Class B common stock is convertible into shares of common stock on a one-for-one basis. Class B common stock has 10 votes per share . There were 146 of such shares outstanding at June 30, 2021 and 2020. Class C Common Stock On April 3, 1995, the stockholders ratified a proposal creating a new Class C common stock and authorized the exchange offering of three shares of Class C common stock for each share of the Company’s outstanding Class B common stock. The Class C common stock has 25 votes per share , as compared to 10 votes per share for the Class B common stock and one vote per share for the common stock. The Class C common stock was offered on a three-for-one basis to the holders of the Class B common stock. Although having greater voting power, each share of Class C common stock has only one-third of the rights of a share of Class B common stock to dividends and distributions. Class C common stock is convertible into shares of common stock on a three-for-one basis. Class A Non-Voting Preferred Stock On April 3, 1995, the stockholders ratified a proposal consisting of the creation of a new class of Class A non-voting preferred stock with special dividend rights and the declaration of a stock dividend on the Company’s common stock consisting of one share of Class A non-voting preferred stock for every five shares of common stock. The stock dividend was payable to holders of common stock on October 20, 1995. Class A non-voting preferred stock issued pursuant to such stock dividend approximates 313,000 shares. The Class A non-voting preferred stock is entitled to a special dividend equal to 3-1/4% of first $10 million, 4-1/2% of next $20 million and 5-1/2% on amounts in excess of $30 million of the amount of any cash awards or settlements received by the Company in connection with the enforcement of five of the Company’s patents in its patent lawsuits, less the revised special dividend payable on the common stock with respect to one of the Company’s patents. The Class A non-voting preferred stock participates on an equal per share basis with the common stock in any dividends declared and ranks equally with the common stock on distribution rights, liquidation rights and other rights and preferences (other than the voting rights). Stock Bonus Plans On April 23, 2010, the Board approved the 2010 Stock Bonus Plan. The plan entitles the Company to reserve 2,000,000 shares of common stock. On August 10, 2010, the Company filed Form S-8 to register the 2,000,000 shares. As of June 30, 2021, 450,177 shares of common stock of FONAR were available for future grant under this plan. For the years ended June 30, 2021 and 2020, 106,747 and 89,981 shares were issued respectively, of which $ 83,277 and $ 0 were expensed and included in selling, general and administrative expenses for the years ended June 30, 2021 and 2020, respectively. Options The Company had stock option plans, which provide for the awarding of incentive and non-qualified stock options to employees, directors and consultants who may contribute to the success of the Company. The options granted vest either immediately or ratably over a period of time from the date of grant, typically three or four years, at a price determined by the Board of Directors or a committee of the Board of Directors, generally the fair value of the Company’s common stock at the date of grant. The options must be exercised within ten years from the date of grant.

NOTE 10 _ CONTROLLING AND NONCO

NOTE 10 – CONTROLLING AND NONCONTROLLING INTERESTS	12 Months Ended
	Jun. 30, 2021
Noncontrolling Interest [Abstract]
NOTE 10 – CONTROLLING AND NONCONTROLLING INTERESTS	NOTE 10 – CONTROLLING AND NONCONTROLLING INTERESTS On February 13, 2013 the Company entered into an agreement with outside investors to acquire a 50.5 % controlling interest in a newly formed limited liability company, Health Diagnostics Management LLC (HDM). According to the February 13, 2013 LLC operating agreement of HDM there are two classes of members; Class A members and one Class B member. The Class A members have an ownership interest of 49.5 % of HDM. The Class B member (HMCA) has an ownership of 50.5 % of HDM. On all matters on which members may vote every member is entitled to cast the percentage of votes equal to their percentage of ownership interest. Profits and losses on all items of income, gain or loss, deductions or other allocations of the Company will be allocated among the members in the same proportions as their membership interests in the Company bear to all the Class A and Class B membership interests of the Company in the aggregate outstanding. All of the depreciation and amortization of the assets of the Company will be allocated solely to the Class A members, unless and until their interests have been redeemed by the Company in full pursuant to the provisions of the operating agreement. The Company contributed $ 20,200,000 to HDM and the group of outside investors contributed $ 19,800,000 for its non-controlling membership interest. On March 5, 2013 HDM purchased from Health Diagnostics, LLC (“HD”) and certain of its subsidiaries, a business managing twelve ( 12 ) Stand-Up MRI Centers and two ( 2 ) other scanning centers located in the States of New York and Florida for a total purchase price (including consideration of $ 1.5 million to outside investors) aggregating $ 35.9 million. Concurrently with the acquisition, HDM entered into several consulting and non-competition agreements for a consideration of $ 4.1 million. The acquisition was accounted for using the purchase method in accordance with ASC 805, “Business Combinations”. The Company recognized and measured goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired. On January 8, 2015, the Company purchased 20% of the Class A members ownership interest at a cost of $ 4,971,094 . The Company has a 60.4 % ownership interest in HDM after this transaction. Amount of each class of HDM members’ equity as of June 30, 2021 and 2020 Class A And B Members' Equity (HDM Acquisition) June 30, 2021 June 30, 2020 Class A Members Class B Member Class A Members Class B Member Opening Members’ Equity $ 55,253 $ 39,850,419 $ 2,155,725 $ 36,543,786 Share of Net Income 3,466,223 17,402,961 3,464,528 16,291,633 Distributions (6,570,000 ) (15,330,000 ) (5,565,000 ) (12,985,000 ) Ending Members’ Equity $ (3,048,524 ) $ 41,923,380 $ 55,253 $ 39,850,419

NOTE 11 - LONG-TERM DEBT, NOTES

NOTE 11 - LONG-TERM DEBT, NOTES PAYABLE AND CAPITAL LEASES	12 Months Ended
	Jun. 30, 2021
Leases [Abstract]
NOTE 11 - LONG-TERM DEBT, NOTES PAYABLE AND CAPITAL LEASES	NOTE 11 - LONG-TERM DEBT, NOTES PAYABLE AND CAPITAL LEASES Long-term debt, notes payable and capital leases consist of the following: Long-term debt, notes payable and capital leases 2021 2020 Note payable requiring monthly payments of interest at a rate of 7 % until May 2009 followed by 240 monthly payments of $ 4,472 through October 2026 . The loan is collateralized by a building with a net book value of $ 413,330 as of June 30, 2021. $ 232,696 $ 273,031 Note payable received under the Paycheck Protection Program (‘PPP’) which was established as part of the Coronavirus Aid, Relief and Economic Security Act (“Cares Act’) that provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses. The loans and accrued interest are forgivable after 24 weeks as long as the proceeds are used for eligible purposes, including payroll, benefits, rent and utilities and maintains certain payroll levels. The unforgiven portion of the PPP loan is payable over 5 five years at an interest rate of 1 %, with a deferral of payments for the first six months. The proceeds from the note payable were received on June 30, 2020. This note was forgiven in August 2021. 700,764 700,764 The revolving credit note was extended to August 2021. The Company can borrow up to $ 10,000,000 and prepay the loan in whole or part in multiples of $100,000 at any time without penalty. The note bears interest at a rate of 4.0 % per annum and is payable monthly. The loan is collateralized by substantially all of the Company’s assets. The loan also contains certain financial covenants that must be met on a periodic basis. The Company still has the ability to draw down on the line. See Note 21. — — 933,460 973,795 Less: Current portion 173,206 108,379 $ 760,254 $ 865,416 The maturities of debt over the next five years and thereafter are as follows: Maturities Of Long-Term Debt Years Ending June 30, 2022 $ 173,206 2023 180,972 2024 183,919 2025 187,155 2026 190,601 Thereafter 17,607 Long-Term Debt Over Five Years and Thereafter $ 933,460

NOTE 12 - INCOME TAXES

NOTE 12 - INCOME TAXES	12 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
NOTE 12 - INCOME TAXES	NOTE 12 - INCOME TAXES ASC topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a corporate tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the benefit recognized and measured pursuant to the interpretation are referred to as unrecognized benefits. A liability is recognized (or amount of net operating loss carryforward or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC topic 740. The Company believes there are no uncertain tax positions in prior years tax filings and therefore it has not recorded a liability for unrecognized tax benefits. In accordance with ASC topic 740, interest costs related to unrecognized tax benefits are required to be calculated (if applicable) and would be classified as “Interest expense, net. Penalties if incurred would be recognized as a component of “Selling, general and administrative” expenses. The Company files corporate income tax returns in the United States (federal) and in various state and local jurisdictions. In most instances, the Company is no longer subject to federal, state and local income tax examinations by tax authorities for years prior to 2016 for federal and 2015 for state. The Company has recorded a deferred tax asset of $ 15,958,961 and a deferred tax liability of $ 238,316 as of June 30, 2021, primarily relating to its net Federal operating loss carryforwards of approximately $ 35,574,000 available to offset future taxable income through 2031. In addition the Company has state operating loss carryforwards of approximately $ 7,094,000 and city operating loss carryforwards of approximately $ 2,470,000 . The net operating losses begin to expire in 2025 for federal tax and state income tax purposes. Future ownership changes as determined under Section 382 of the Internal Revenue code could further limit the utilization of net operating loss carryforwards. As of June 30, 2021, no such changes in ownership have occurred. The ultimate realization of deferred tax assets is dependent on the generation of future taxable income during the periods in which temporary differences become deductible or when such net operating losses can be utilized. The Company considers projected future taxable income, the regulatory environment of the industry, and tax planning strategies in making this assessment. At present, the Company believes that it is more likely than not that the benefits from certain deferred tax asset carryforwards, will not all be fully realized. In recognition of this inherent risk, a valuation allowance was established for the partial value of the deferred tax asset, which principally related to research and development tax credits. A valuation allowance will be maintained until sufficient positive evidence exists to support the reversal of the remainder of the valuation. The valuation allowance for deferred tax assets decreased during the year ended June 30, 2021, by approximately $ 3,547,000 . The valuation allowance decreased by approximately $ 195,000 during the year ended June 30, 2020. On March 27, 2020 Congress enacted the CARES Act (Coronavirus Aid, Relief and Economic Security Act). The Act provides numerous tax provisions and other stimulus measures, including temporary changes regarding prior and future operation losses, temporary changes to prior and future limitations on interest deductions, temporary suspension of certain payment requirements for the employer portion of Social Security taxes, technical corrections to prior tax legislation for tax depreciation of certain qualified improvement property and enhanced recoverability of AMT tax credits. At the present time, the only impact of the CARES Act to the Company is allowing a full reimbursement of $1,342,370 of tax credits relating to the alternative minimum tax credits. The Company received the first half payment in June 2020. The balance of alternative minimum tax credits of $671,185 was received in July 2020. Previously, these credits were to be refunded over a 3 year period. As we continue to monitor tax implications of the CARES Act and other state and federal stimulus tax legislation, we may make adjustments to our estimates and record additional amounts for tax assets and liabilities. Components of the provision (benefit) for income taxes are as follows: Components Of The Benefit Provision For Income Taxes Years Ended June 30 Current: 2021 2020 Federal $ $ (187,255 ) State 1,136,514 513,204 Subtotal 1,136,514 325,949 Deferred: Federal deferred taxes 2,718,046 1,953,349 State deferred taxes 136,960 165,480 Subtotal 2,855,006 2,118,829 Provision (Benefit) for Income Taxes - Net $ 3,991,520 $ 2,444,778 A reconciliation of the federal statutory income tax rate to the Company’s effective tax rate as reported is as follows: Reconciliation Of Federal Statutory Income Tax Rate To Company's Effective Tax Rate Years Ended June 30, 2021 2020 Taxes at federal statutory rate 21.0 % 21.0 % State and local income taxes (benefit), net of federal benefit 3.3 % 4.0 % Non Controlling interest (4.9 )% (6.1 )% Expiration of tax credits 4.6 % 0.2 % Return to provision adjustments 6.1 % — % Change in the valuation allowance (20.0 )% 0.3 % Other 12.5 % (2.1 )% Effective income tax rate 22.6 % 17.3 % As of June 30, 2021, the Company has net operating loss (“NOL”) carryforwards of approximately $35,574,000 that will be available to offset future taxable income. The utilization of certain of the NOLs is limited by separate return limitation year rules pursuant to Section 1502 of the Internal Revenue Code. The Company has, for federal income tax purposes, research and development tax credits and investments tax credits carryforwards aggregating $ 3,733,000 . However, the realization of these credits may be limited as a result of expiring prior to their utilization. These credits can only be applied after all net operating losses have been used, which expire through 2031. As such, the Company has established a valuation reserve for anticipated unused credits of $ 890,000 . In addition, for New York State income tax purposes, the Company has tax credit carryforwards aggregating approximately $ 11,000 which, are accounted for under the flow-through method. The Company was also under audit with New York State for income tax and was assessed additional taxes of $ 423,272 plus interest and penalties. These amounts are accrued for at June 30, 2021 and included in other current liabilities and were paid in August 2021. Significant components of the Company’s deferred tax assets and liabilities at June 30, 2021 and 2020 are as follows: Components Of Company's Deferred Tax Assets And Liabilities June 30, 2021 2020 Deferred tax assets: Allowance for doubtful accounts $ 3,827,382 $ 3,946,801 Non-deductible accruals 749,902 693,833 Net operating carryforwards 8,285,163 13,720,637 Tax credits 3,732,650 4,647,217 Inventory 66,316 69,940 Property and equipment and depreciation 187,632 168,371 Deferred Tax Assets - gross 16,849,045 23,246,799 Valuation allowance (890,084 ) (4,437,042 ) Total deferred tax assets 15,958,961 18,809,757 Intangibles (238,316 ) (234,106 ) Total deferred tax liabilities (238,316 ) (234,106 ) Net deferred tax asset $ 15,720,645 $ 18,575,651

NOTE 13 - OTHER CURRENT LIABILI

NOTE 13 - OTHER CURRENT LIABILITIES	12 Months Ended
	Jun. 30, 2021
Payables and Accruals [Abstract]
NOTE 13 - OTHER CURRENT LIABILITIES	NOTE 13 - OTHER CURRENT LIABILITIES Included in other current liabilities are the following: Other Current Liabilities June 30, 2021 2020 Accrued salaries, commissions and payroll taxes $ 5,406,982 $ 4,491,941 Litigation accruals 900,000 442,802 Sales tax payable 644,623 1,353,200 State income taxes payable 774,234 — Legal and other professional fees 37,827 112,867 Accounting fees 127,262 120,000 Self-funded health insurance reserve 62,548 86,504 Accrued interest and penalty 493,042 877,787 Other 715,600 699,997 Other current liabilities $ 9,162,118 $ 8,185,098

NOTE 14 - COMMITMENTS AND CONTI

NOTE 14 - COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
NOTE 14 - COMMITMENTS AND CONTINGENCIES	NOTE 14 - COMMITMENTS AND CONTINGENCIES Leases The Company rents its operating facilities and certain equipment, pursuant to operating lease agreements expiring at various dates through March 2030. The leases for certain facilities contain escalation clauses relating to increases in real property taxes as well as certain maintenance costs. Rent expense for operating leases approximated $ 6,146,000 and $ 5,136,000 , for the years ended June 30, 2021 and 2020, respectively. The Company received approval from the Suffolk County IDA on February 29, 2016 of a 50 % property tax abatement, valued at $ 440,000 , over a 10 year period commencing January 2017. Employee Benefit Plans The Company has a non-contributory 401(k) Plan (the “401(k) Plan”). The 401(k) Plan covers all non-union employees who are at least 21 years of age with no minimum service requirements. There were $ 36,799 and $ 0 employer contributions to the Plan for the years ended June 30, 2021 and 2020. The stockholders of the Company approved the 2000 Employee Stock Purchase Plan (“ESPP”) at the Company’s annual stockholders’ meeting in April 2000. The ESPP provides for eligible employees to acquire common stock of the Company at a discount, not to exceed 15%. This plan has not been put into effect as of June 30, 2021. Litigation In September 2019, The Company was notified by one of its landlords that it was required to vacate the premises within 180 days under the demolition clause in the lease. The Company believes the lease renewal which was not negotiated in good faith since the renewal was negotiated in February 2018. The Company is in the process of relocating to a new location but the original lease provided for penalty payments in the event that the Company had not vacated the leased space. The Company has been making normal rent payments throughout the course of the arbitration proceedings. The Company is estimating the leasehold holdover charges to be approximately $900,000. As of June 30, 2021 this amount has been accrued for under other current liabilities. In September 2020, the Company entered into a settlement agreement with an unrelated third party for a claim made during March 2018 which was scheduled for arbitration. The settlement was for $1.2 million of which $900,000 was paid by the Company’s insurance on September 15, 2020 with the remaining $315,000 paid by the Company on September 28, 2020. Other Matters The Company is subject to other legal proceedings and claims arising from the ordinary course of its business, including personal injury, customer contract and employment claims besides the claim above. In the opinion of management, and with consultation with legal council, the aggregate liability, if any, with respect to such actions, will not have a material adverse effect on the consolidated financial position or results of operations of the Company. The Company has satisfied most of its delinquencies in filing sales tax returns for certain states, for which the Company has transacted business. The Company has recorded tax obligations of approximately $ 645,000 plus interest and penalties of approximately $ 232,000 until the remaining states have been resolved. The Company maintains a self-funded health insurance program with a stop-loss umbrella policy with a third party insurer to limit the maximum potential liability for individual claims to $ 110,000 per person and for a maximum potential claim liability based on member enrollment. With respect to this program, the Company considers historical and projected medical utilization data when estimating its health insurance program liability and related expense. As of June 30, 2021 and 2020, the Company had approximately $ 63,000 and $ 87,000 , respectively, in reserve for its self-funded health insurance programs. The reserves are included in “Other current liabilities” in the consolidated balance sheets. The Company regularly analyzes its reserves for incurred but not reported claims, and for reported but not paid claims related to its reinsurance and self-funded insurance programs. The Company believes its reserves are adequate. However, significant judgment is involved in assessing these reserves such as assessing historical paid claims, average lags between the claims’ incurred date, reported dates and paid dates, and the frequency and severity of claims. There may be differences between actual settlement amounts and recorded reserves and any resulting adjustments are included in expense once a probable amount is known. There were no significant adjustments recorded in the years covered by this report.

NOTE 15 - SUPPLEMENTAL CASH FLO

NOTE 15 - SUPPLEMENTAL CASH FLOW INFORMATION	12 Months Ended
	Jun. 30, 2021
Supplemental Cash Flow Elements [Abstract]
NOTE 15 - SUPPLEMENTAL CASH FLOW INFORMATION	NOTE 15 - SUPPLEMENTAL CASH FLOW INFORMATION During the years ended June 30, 2021 and 2020 the Company paid $ 75,178 and $ 137,200 for interest, respectively. During the years ended June 30, 2021 and 2020 the Company paid $ 261,032 and $ 228,204 for income taxes, respectively. During the years ended June 30, 2021 and 2020, the Company issued 102,364 and 89,981 shares of common stock for costs and expenses totaling $ 1,940,821 and $ 1,990,380 , respectively. During the year ended June 30, 2020 the Company entered into a capital lease for the purchase of equipment in the amount of $ 1,350,000 . During the year, the Company resolved certain sales tax liabilities and was able to reverse accrued interest and penalties in the amount of $ 602,000 which has been recorded under selling, general and administrative expenses.

NOTE 16 _ RELATED PARTY TRANSAC

NOTE 16 – RELATED PARTY TRANSACTIONS	12 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
NOTE 16 – RELATED PARTY TRANSACTIONS	NOTE 16 – RELATED PARTY TRANSACTIONS The CEO and President of the Company is a minority owner of a billing company, which performs billing and collection services with respect to No-Fault and Workers’ Compensation claims of the Company’s clients. The monthly fee charged to the Company was $85,000. The Company terminated this agreement on January 1, 2021. On June 1, 2017, the Company also entered into a one year renewable agreement to provide IT services to the billing company for a monthly fee of $23,884. The agreement was renewed on June 1, 2021 for another year. Bensonhurst MRI Limited Partnership, in which the CEO and President of the Company holds an interest, is party to an agreement with the Company for the service and maintenance of its Upright MRI Scanner for a price of $110,000 per annum.

NOTE 17 - SEGMENT AND RELATED I

NOTE 17 - SEGMENT AND RELATED INFORMATION	12 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
NOTE 17 - SEGMENT AND RELATED INFORMATION	NOTE 17 - SEGMENT AND RELATED INFORMATION The Company provides segment data in accordance with the provisions of ASC topic 280, “Disclosures about Segments of an Enterprise and Related Information”. The Company operates in two industry segments - manufacturing and the servicing of medical equipment and management of diagnostic imaging centers. The accounting policies of the segments are the same as those described in the summary of significant accounting policies. All intersegment sales are market-based. The Company evaluates performance based on income or loss from operations. Summarized financial information concerning the Company’s reportable segments is shown in the following table: Summarized Segment Financial Information Manufacturing and Servicing of Medical Management of Diagnostic Imaging Fiscal 2021: Equipment Center Totals Net revenues from external customers $ 9,037,091 $ 80,892,674 $ 89,929,765 Intersegment net revenues * $ 901,250 $ — $ 901,250 (Loss) Income from operations $ (3,410,189 ) $ 20,507,804 $ 17,097,615 Depreciation and amortization $ 264,830 $ 3,816,857 $ 4,081,687 Compensatory element of stock issuances $ 83,277 $ — $ 83,277 Total identifiable assets $ 24,592,582 $ 164,913,613 $ 189,506,195 Capital expenditures $ 291,294 $ 3,405,502 $ 3,696,796 Fiscal 2020: Net revenues from external customers $ 8,463,103 $ 77,227,359 $ 85,690,462 Intersegment net revenues * $ 875,000 $ — $ 875,000 (Loss) Income from operations $ (6,425,411 ) $ 20,076,327 $ 13,650,916 Depreciation and amortization $ 368,498 $ 3,540,150 $ 3,908,648 Compensatory element of stock issuances $ — $ — $ — Total identifiable assets $ 30,492,757 $ 149,790,753 $ 180,283,510 Capital expenditures $ 2,440,640 $ 4,981,773 $ 7,422,413 * Amounts eliminated in consolidation Export Product Sales The Company’s areas of operations are principally in the United States. The Company had export sales of medical equipment amounting to 69.3 % and 20.2 % of product sales revenues to third parties for the years ended June 30, 2021 and 2020, respectively. The foreign product sales, as a percentage of product sales to unrelated parties, were made to customers in the following countries: Export Product Sales For the Years Ended June 30 2021 2020 Dominican Republic 67.0 % — % Canada 0.1 — Germany 2.1 20.2 Puerto Rico 0.1 — 69.3 % 20.2 % Foreign Service and Repair Fees The Company’s areas of service and repair are principally in the United States. The Company had foreign revenues of service and repair of medical equipment amounting to 4.5 % and 5.6 % of consolidated net service and repair fees for the years ended June 30, 2021 and 2020 respectively. Foreign service and repair fees, as a percentage of total service and repair fees, were provided principally to the following countries: Foreign Service and Repair Fees For the Years Ended June 30, 2021 2020 Puerto Rico 1.5 % 1.6 % Switzerland 0.3 0.3 Germany 1.5 1.5 England 0.6 0.7 Canada 0.3 0.3 Greece 0.3 0.2 Australia — 1.0 4.5 % 5.6 % The Company does not have any material assets outside of the United States.

NOTE 18 _ ACQUISTION

NOTE 18 – ACQUISTION	12 Months Ended
	Jun. 30, 2021
Business Combination and Asset Acquisition [Abstract]
NOTE 18 – ACQUISTION	NOTE 18 – ACQUISTION On March 29, 2021, the Company completed the acquisition of certain assets of Rockland Management Group, located in West Yonkers. The Company used an incremental borrowing rate of 4% to value the right to use asset in connection with the assumed operating lease obligation. We made a preliminary fair value determination of the acquired assets and assumed liabilities as follows: Fair value assets and assumed liabilities Property and equipment $ 650,000 Right to use assets 434,219 Intangible assets 150,000 Security Deposit 38,628 Right to use liability (434,219 ) Goodwill 283,880 Total purchase consideration $ 1,122,508 In accordance with ASC 805-10-25-1, Business Combinations – Overall Recognition, the Company recorded the transaction as a business combination. ASC 805-10-25-1 provides the requirements of recording the transaction by applying the acquisition method. The acquisition method requires the Company to determine if the assets and liabilities acquired are a business or not. Under ASC 805-10-25-1, it must be determined if there is a specific acquisition party, acquisition date, identifiable assets acquired and liabilities assumed and you must be able to recognized and measure goodwill or a gain from the purchase. Based upon this guidance, the acquisition had been recorded as a business combination. The net assets acquired and consideration is as follow: Net assets acquired Leasehold Improvements $ 550,000 Diagnostic Equipment 100,000 Customer Lists 100,000 Covenant Not to Compete 50,000 Security Deposit 38,628 Closing costs - expensed 3,478 Goodwill 283,880 Cash Consideration Paid $ 1,125,986 The results of operations of Rockland Management Group were diminutive and did not affect the pro forma results of operations.

NOTE 19 _ ALLOWANCE FOR DOUBTFU

NOTE 19 – ALLOWANCE FOR DOUBTFUL ACCOUNTS	12 Months Ended
	Jun. 30, 2021
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
NOTE 19 – ALLOWANCE FOR DOUBTFUL ACCOUNTS	NOTE 19 – ALLOWANCE FOR DOUBTFUL ACCOUNTS The following represents a summary of allowance for doubtful accounts for the years ended June 30, 2021 and 2020 respectively: Summary of Allowance For Doubtful Accounts Description Balance Additions (1) Deductions Balance Accounts receivable $ 514,561 $ — $ 72,291 $ 442,270 Management and other fees receivable 11,063,233 4,723,645 — 15,786,878 Management and other fees receivable - related medical practices 3,322,055 862,344 — 4,184,399 Notes receivable 777,354 — — 777,354 Balance Balance Description June 30, 2019 Additions Deductions June 30, 2020 Accounts receivable $ 190,244 $ 380,000 $ 55,683 $ 514,561 Management and other fees receivable 9,404,944 3,526,742 (1,868,453 ) 11,063,233 Management and other fees receivable - related medical practices 2,310,731 1,011,324 — 3,322,055 Notes receivable — 777,354 — 777,354 (1) Included in provision for bad debts.

NOTE 20 - QUARTERLY FINANCIAL D

NOTE 20 - QUARTERLY FINANCIAL DATA (UNAUDITED)	12 Months Ended
	Jun. 30, 2021
Quarterly Financial Information Disclosure [Abstract]
NOTE 20 - QUARTERLY FINANCIAL DATA (UNAUDITED)	NOTE 20 - QUARTERLY FINANCIAL DATA (UNAUDITED) (000’s omitted, except per share data) Quarterly Financial Data September 30, 2020 December 30, 2020 March 31, 2021 June 30, 2021 Total Total Revenues – Net $ 20,979 $ 21,164 $ 23,090 $ 24,697 $ 89,930 Total Costs and Expenses 16,829 16,182 18,968 20,853 72,832 Net Income 3,251 3,928 4,299 2,196 13,674 Basic Net Income Per Common Share Available to Common Stockholders $ 0.37 $ 0.45 $ 0.55 $ 0.10 $ 1.47 Diluted Net Income Per Common Share Available to Common Stockholders $ 0.36 $ 0.44 $ 0.54 $ 0.11 $ 1.45 September 30, 2019 December 30, 2019 March 31, 2020 June 30, 2020 Total Total Revenues – Net $ 21,747 $ 21,451 $ 21,686 $ 20,806 $ 85,690 Total Costs and Expenses 16,261 16,430 19,071 20,278 72,040 Net Income 4,506 4,209 1,914 1,076 11,705 Basic Net Income Per Common Share Available to Common Stockholders $ 0.48 $ 0.45 $ 0.18 $ 0.09 $ 1.20 Diluted Net Income Per Common Share Available to Common Stockholders $ 0.47 $ 0.44 $ 0.18 $ 0.09 $ 1.18

NOTE 21 _ SUBSEQUENT EVENTS

NOTE 21 – SUBSEQUENT EVENTS	12 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
NOTE 21 – SUBSEQUENT EVENTS	NOTE 21 – SUBSEQUENT EVENTS The Company evaluates events that have occurred after the balance sheet date, but before the consolidated financial statements are issued. During August 2021 the Company amended their revolving credit agreement. The agreement was extended to August 2022. The interest rate on borrowings remains at 4 % along with certain financial covenants. The loan of $ 700,764 received under the Paycheck Protection Program was forgiven in August 2021.

NOTE 2 - SUMMARY OF SIGNIFICA_2

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries and partnerships. The operating activities of subsidiaries are included in the accompanying consolidated statements from the date of acquisition. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The most significant estimates relate to receivable allowances, intangible assets, income taxes and related tax asset valuation allowances, useful lives of property and equipment, contingencies, revenue recognition and the assessment of litigation. In addition, healthcare industry reforms and reimbursement practices will continue to impact the Company’s operations and the determination of contractual and other allowance estimates. Actual results could differ from those estimates.
Inventories	Inventories Inventories consist of purchased parts, components and supplies, as well as work-in-process, and are stated at the lower of cost, determined on the first-in, first-out method, or market.
Property and Equipment	Property and Equipment Property and equipment procured in the normal course of business is stated at cost. Property and equipment purchased in connection with an acquisition is stated at its estimated fair value, generally based on an appraisal. Property and equipment is being depreciated for financial accounting purposes using the straight-line method over their estimated useful lives. Leasehold improvements are being amortized over the shorter of the useful life or the remaining lease term. Upon retirement or other disposition of these assets, the cost and related accumulated depreciation of these assets are removed from the accounts and the resulting gains or losses are reflected in the results of operations. Expenses for maintenance and repairs are charged to operations. Renewals and betterments are capitalized. Maintenance and repair expenses totaled approximately $ 2,051,000 and $ 1,870,000 for the years ended June 30, 2021 and 2020 respectively. The estimated useful lives in years are generally as follows: Estimated Useful Life in Years for Property and Equipment Diagnostic equipment 5 – 13 Research, development and demonstration equipment 3 - 7 Machinery and equipment 2 - 7 Furniture and fixtures 3 - 9 Leasehold improvements 3 – 10 Building 28
Long-Lived Assets	Long-Lived Assets The Company periodically assesses the recoverability of long-lived assets, including property and equipment and intangibles, other than goodwill, when there are indications of potential impairment, based on estimates of undiscounted future cash flows. The amount of impairment is calculated by comparing anticipated discounted future cash flows with the carrying value of the related asset. In performing this analysis, management considers such factors as current results, trends, and future prospects, in addition to other economic factors.
Other Intangible Assets	Other Intangible Assets 1) Patents and Copyrights Amortization is calculated on the straight-line basis over 15 years. 2) Non-Competition Agreements The non-competition agreements are being amortized on the straight line basis over the length of the agreement ( 7 years). 3) Customer Relationships Amortization is calculated on the straight line basis over 20 years.
Goodwill	Goodwill Generally accepted accounting principles in the United States require the Company to perform a goodwill impairment test annually and more frequently when negative conditions or a triggering event arises. Impairment of goodwill is tested at the reporting unit level by comparing the reporting unit’s carrying amount, including goodwill to the fair value of the reporting unit. If the carrying amount of the reporting unit exceeds its fair value, goodwill is considered potentially impaired and a second step is performed to measure the amount of impairment loss, if any.
Acquired assets and assumed liabilities	Acquired assets and assumed liabilities Pursuant to ASC No. 805-10-25, if the initial accounting for a business combination is incomplete by the end of the reporting period in which the combination occurs, but during the allowed measurement period not to exceed one year from the acquisition date, the Company adjusts the provisional amounts recognized at the acquisition date by means of adjusting the amount recognized for goodwill.
Revenue Recognition	Revenue Recognition Revenue on sales contracts for scanners, included in “product sales” in the accompanying consolidated statements of operations, is recognized under the percentage-of-completion method in accordance with FASB ASC 606, “Revenue Recognition – Construction-Type and Production-Type Contracts”. The Company manufactures its scanners under specific contracts that provide for progress payments. Production and installation take approximately three to six months. Revenue on scanner service contracts is recognized on the straight-line method over the related contract period, usually one year. Revenue from product sales (upgrades and supplies) is recognized upon shipment. Revenue under management contracts is recognized based upon contractual agreements for management services rendered by the Company primarily under various long-term agreements with various medical providers (the “PCs”). As of June 30, 2021, the Company has twenty two 22 management agreements of which three 3 are with PC’s owned by Raymond V. Damadian, M.D., Chairman of the Board of FONAR (“the Related medical practices”) and nineteen 19 are with PC’s, which are all located in the state of New York (“the New York PC’s”), owned by two unrelated radiologists. The contractual fees for services rendered to the PCs consists of fixed monthly fees per diagnostic imaging facility ranging from approximately $ 77,000 to $ 522,000 . All fees are re-negotiable at the anniversary of the agreements and each year thereafter. The Company records a provision for bad debts for estimated uncollectible fees, which is reflected in other operating expenses on the Statement of Operations. All fees are re-negotiable at the anniversary of the agreements and each year thereafter. On July 1, 2018, the Company adopted the new revenue recognition accounting standard issued by the Financial Accounting Standards Board (“FASB”) and codified in the ASC as topic 606 (“ASC 606”). The revenue recognition standard in ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires expanded disclosures regarding the Company’s revenue recognition policies and significant judgments employed in the determination of revenue. The Company applied the modified retrospective approach to all contracts when adopting ASC 606. As a result, at the adoption of ASC 606 the majority of what was previously classified as the provision for bad debts in the statement of operations is now reflected as implicit price concessions (as defined in ASC 606) and therefore included as a reduction to net operating revenues in 2019. For changes in credit issues not assessed at the date of service, the Company will prospectively recognize those amounts in other operating expenses on the statement of operations. For periods prior to the adoption of ASC 606, the provision for bad debts has been presented consistent with the previous revenue recognition standards that required it to be presented separately as a component of net operating revenues. Our revenues generally relate to net patient fees received from various payers and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. The Company’s patient fee revenues, net of contractual allowances and discounts less the provision for bad debts for the years ended June 30, 2021 and 2020 are summarized in the following table. Patient Fee Revenue - Net For the Years Ended June 30 2021 2020 Commercial Insurance/ Managed Care $ 4,100,440 $ 4,545,987 Medicare/Medicaid 968,055 1,038,288 Workers’ Compensation/Personal Injury 15,011,111 16,028,737 Other 3,227,783 882,248 Net Patient Fee Revenue $ 23,307,389 $ 22,495,260
Research and Development Costs	Research and Development Costs Research and development costs are charged to expense as incurred. The costs of equipment that are acquired or constructed for research and development activities, and have alternative future uses (either in research and development, marketing or production), are classified as property and equipment and depreciated over their estimated useful lives.
Advertising Costs	Advertising Costs Advertising costs are expensed as incurred. Advertising expense approximated $ 633,000 and $ 566,000 and for the years ended June 30, 2021 and 2020, respectively.
Shipping Costs	Shipping Costs The Company’s shipping and handling costs are included in revenue from product sales and the related expense included in costs related to product sales is $ 8,215 and $ 12,056 for the years ended June 30, 2021 and 2020 respectively.
Income Taxes	Income Taxes Deferred tax assets and liabilities are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse.
Customer Advances	Customer Advances Cash advances and progress payments received on sales orders are reflected as customer advances until such time as revenue recognition occurs.
Earnings Per Share	Earnings Per Share Basic earnings per share (“EPS”) is computed by dividing net income available to common stockholders by the weighted average number of shares of common stock outstanding during the period. In accordance with ASC topic 260-10, “Participating Securities and the Two-Class Method”, the Company used the Two-Class method for calculating basic earnings per share and applied the if converted method in calculating diluted earnings per share for the years ended June 30, 2021 and 2020. Diluted EPS reflects the potential dilution from the exercise or conversion of all dilutive securities into common stock based on the average market price of common shares outstanding during the period. For the years ended June 30, 2021 and 2020, diluted EPS for common shareholders includes 127,504 shares upon conversion of Class C Common. Earnings Per Share June 30, 2021 Basic Total Common Stock Class C Common Stock Numerator: Net income available to common stockholders $ 10,207,588 $ 9,592,134 $ 156,744 Denominator: Weighted average shares outstanding 6,505,283 6,505,283 382,513 Basic income per common share $ 1.57 $ 1.47 $ 0.41 Diluted Denominator: Weighted average shares outstanding 6,505,283 382,513 Class C Common Stock 127,504 — Total Denominator for diluted earnings per share 6,632,787 382,513 Diluted income per common share $ 1.45 $ 0.41 June 30, 2020 Basic Total Common Stock Class C Common Stock Numerator: Net income available to common stockholders $ 8,240,205 $ 7,735,650 $ 128,500 Denominator: Weighted average shares outstanding 6,443,713 6,443,713 382,513 Basic income per common share $ 1.28 $ 1.20 $ 0.34 Diluted Denominator: Weighted average shares outstanding 6,443,713 382,513 Class C Common Stock 127,504 — Total Denominator for diluted earnings per share 6,571,217 382,513 Diluted income per common share $ 1.18 $ 0.34
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents includes cash on hand, cash in banks, investments in certificates of deposit with original maturities of 90 days or less, and money market funds.
Short Term Investments	Short Term Investments Short term investments include certificates of deposit with original maturities of greater than 90 days.
Concentration of Credit Risk	Concentration of Credit Risk Cash: The Company maintains its cash and cash equivalents with various financial institutions, which exceed federally insured limits throughout the year. At June 30, 2021, the Company had cash on deposit of approximately $ 42,609,000 in excess of federally insured limits of $ 250,000 . Related Parties: Net revenues from related parties accounted for approximately 12 % and 12 % of the consolidated net revenues for the years ended June 30, 2021 and 2020, respectively. Net management fee receivables from the related party medical practices accounted for approximately 13 % and 13 % of the consolidated accounts receivable for the years ended June 30, 2021 and 2020, respectively. See Note 3 regarding the Company’s concentrations in the healthcare industry.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The financial statements include various estimated fair value information at June 30, 2021 and 2020, as required by ASC topic 820, “Disclosures about Fair Value of Financial Instruments”. Such information, which pertains to the Company’s financial instruments, is based on the requirements set forth in that Statement and does not purport to represent the aggregate net fair value to the Company. The Company has established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring and revaluing fair value. These tiers include, Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The following methods and assumptions were used to estimate the fair value of each class of financial instruments for which it is practicable to estimate that value: Cash and cash equivalents: The carrying amount approximates fair value because of the short-term maturity of those instruments. Short term investments: The carrying amount approximates fair value because of the short-term maturity of those instruments. Such amounts include Certificates of Deposits with original maturities greater than 90 days. These securities are classified as Level 1. Receivable and accounts payable: The carrying amounts approximate fair value because of the short maturity of those instruments. Notes receivable: The carrying amount approximates fair value because the discounted present value of the cash flow generated by the parties approximates the carrying value of the amounts due to the Company. Long-term debt and notes payable: The carrying amounts of debt and notes payable approximate fair value due to the length of the maturities, the interest rates being tied to market indices and/or due to the interest rates not being significantly different from the current market rates available to the Company. All of the Company’s financial instruments are held for purposes other than trading.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12 (“ASU 2019-12”), Income Taxes (Topic 740). ASU 2019-12 removes certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other areas of the standard. ASU 2019-12 was effective beginning in the first quarter of 2021. Certain amendments in this update must be applied on a prospective basis, certain amendments must be applied on a retrospective basis, and certain amendments must be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings/(deficit) in the period of adoption. The adoption of this update did not have a material impact on our financial statements. In January 2017, the FASB issued Accounting Standards Update (“ASU”) 2017-04, Intangibles – Goodwill and Other (Topic 350). The amendments in this update simplify the test for goodwill impairment by eliminating Step 2 from the impairment test, which required the entity to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining fair value of assets acquired and liabilities assumed in a business combination. The amendments in this update are effective for public companies for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company adopted the Standard on July 1, 2020 and the impact of adopting this guidance had no material impact on our Consolidated Financial Statements. FASB, the Emerging Issues Task Force and the SEC have issued certain other accounting standards, updates, and regulations as of June 30, 2021 that will become effective in subsequent periods; however, management does not believe that any of those updates would have significantly affected our financial accounting measures or disclosures had they been in effect during 2021 or 2020, and it does not believe that any of those pronouncements will have a significant impact on our consolidated financial statements at the time they become effective.

NOTE 2 - SUMMARY OF SIGNIFICA_3

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Estimated Useful Life in Years for Property and Equipment	Estimated Useful Life in Years for Property and Equipment Diagnostic equipment 5 – 13 Research, development and demonstration equipment 3 - 7 Machinery and equipment 2 - 7 Furniture and fixtures 3 - 9 Leasehold improvements 3 – 10 Building 28
Patient Fee Revenue - Net	Patient Fee Revenue - Net For the Years Ended June 30 2021 2020 Commercial Insurance/ Managed Care $ 4,100,440 $ 4,545,987 Medicare/Medicaid 968,055 1,038,288 Workers’ Compensation/Personal Injury 15,011,111 16,028,737 Other 3,227,783 882,248 Net Patient Fee Revenue $ 23,307,389 $ 22,495,260
Earnings Per Share	Earnings Per Share June 30, 2021 Basic Total Common Stock Class C Common Stock Numerator: Net income available to common stockholders $ 10,207,588 $ 9,592,134 $ 156,744 Denominator: Weighted average shares outstanding 6,505,283 6,505,283 382,513 Basic income per common share $ 1.57 $ 1.47 $ 0.41 Diluted Denominator: Weighted average shares outstanding 6,505,283 382,513 Class C Common Stock 127,504 — Total Denominator for diluted earnings per share 6,632,787 382,513 Diluted income per common share $ 1.45 $ 0.41 June 30, 2020 Basic Total Common Stock Class C Common Stock Numerator: Net income available to common stockholders $ 8,240,205 $ 7,735,650 $ 128,500 Denominator: Weighted average shares outstanding 6,443,713 6,443,713 382,513 Basic income per common share $ 1.28 $ 1.20 $ 0.34 Diluted Denominator: Weighted average shares outstanding 6,443,713 382,513 Class C Common Stock 127,504 — Total Denominator for diluted earnings per share 6,571,217 382,513 Diluted income per common share $ 1.18 $ 0.34

NOTE 3 _ ACCOUNTS RECEIVABLE,_2

NOTE 3 – ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Tables)	12 Months Ended
	Jun. 30, 2021
Receivables [Abstract]
Receivables - Non Current - net	Receivables - Non Current - net 2023 $ 1,020,140 2024 1,020,140 2025 599,545 2026 160,697 Total $ 2,800,522
Total Facilities	Total Facilities For the Year Ended June 30, 2021 2020 Total Facilities Owned or Managed (at Beginning of Year) 25 26 Facilities Added by: Acquisition 1 — Internal development 1 — Managed Facilities Closed — (1 ) Total Facilities Owned or Managed (at End of Year) 27 25

NOTE 4 _ CONTRACT ASSETS AND _2

NOTE 4 – CONTRACT ASSETS AND LIABILITIES (Tables)	12 Months Ended
	Jun. 30, 2021
Regulated Operations [Abstract]
`Costs and Estimated Earnings on Uncompleted Contracts	`Costs and Estimated Earnings on Uncompleted Contracts As of June 30, 2021 2020 Costs incurred on uncompleted contracts $ 294,783 $ 448,437 Estimated earnings 567,978 309,248 Costs and estimated earnings on uncompleted contracts 862,761 757,685 Less: Billings to date 877,500 604,852 Costs and estimated earnings in excess of billings on uncompleted contracts $ (14,739 ) $ 152,833

NOTE 5 _ INVENTORIES (Tables)

NOTE 5 – INVENTORIES (Tables)	12 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
Inventories	Inventories As of June 30, 2021 2020 Purchased parts, components and supplies $ 1,393,329 $ 1,544,036 Work-in-process 270,090 104,734 Inventories $ 1,663,419 $ 1,648,770

NOTE 6 - PROPERTY AND EQUIPME_2

NOTE 6 - PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment As of June 30, 2021 2020 Diagnostic equipment $ 29,826,829 $ 28,434,063 Research, development and demonstration equipment 6,029,551 5,901,961 Machinery and equipment 2,069,055 2,069,055 Furniture and fixtures 3,450,664 3,291,666 Leasehold improvements 12,961,887 10,736,825 Building 939,614 939,614 55,277,600 51,373,184 Less: Accumulated depreciation and amortization 33,427,461 30,009,150 $ 21,850,139 $ 21,364,034

NOTE 7 _ OPERATING & FINANCIN_2

NOTE 7 – OPERATING & FINANCING LEASES (Tables)	12 Months Ended
	Jun. 30, 2021
Note 7 Operating Financing Leases
Reconciliation of operating and financing lease payments	Reconciliation of operating and financing lease payments Year Ending Operating Lease Financing Lease Payments 2022 $ 5,077,656 $ 244,343 2023 5,172,157 244,343 2024 4,837,900 244,343 2025 4,725,550 244,343 2026 4,285,124 244,343 Thereafter 16,950,126 162,898 Present value discount (8,539,725 ) (133,441 ) Total lease liability $ 32,508,788 $ 1,251,172 Weighted Average Remaining Lease Term Operating leases - years 9.4 Finance lease - years 5.6 Weighted Average Discount Rate Operating leases 5.5 % Finance lease 3.6 %
Components of lease expense	Components of lease expense For Year Ended June 30, 2021 June 30, 2020 Operating lease cost $ 6,145,701 $ 5,135,604 Finance lease cost: Depreciation of leased equipment $ 198,881 $ — Interest on lease liabilities 47,472 — Total finance lease cost $ 246,353 $ —
Supplemental cash flow information related to leases	Supplemental cash flow information related to leases For year ended Cash paid for amounts included in the measurement of lease liabilities: June 30, 2021 June 30, 2020 Operating cash flows from operating leases $ 4,970,934 $ 4,170,977 Financing cash flows from financing leases $ 130,038 $ Right-of-use & equipment assets obtained in exchange for lease obligations: Operating leases(1) $ 1,531,889 $ 34,786,611 Financing leases $ — $ 1,325,871

NOTE 8 - OTHER INTANGIBLE ASS_2

NOTE 8 - OTHER INTANGIBLE ASSETS (Tables)	12 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Other Intagible Assets - Net	Other Intagible Assets - Net As of June 30, 2021 2020 Capitalized software development costs $ 7,004,847 $ 7,004,847 Patents and copyrights 5,244,892 5,081,721 Non-competition agreements 4,150,000 4,100,000 Customer relationships 3,900,000 3,800,000 20,299,739 19,986,568 Less: Accumulated amortization 16,262,140 15,877,439 $ 4,037,599 $ 4,109,129
Schedule Of Other Intangible Assets	Schedule Of Other Intangible Assets For the Years Total Patents and Copyrights Non- Customer Relationships 2022 $ 423,209 $ 185,709 $ 37,500 $ 200,000 2023 389,168 189,168 — 200,000 2024 388,867 188,867 — 200,000 2025 383,912 183,912 — 200,000 2026 373,220 173,220 — 200,000 Thereafter 2,079,223 765,056 — 1,314,167 Other intangible assets - net $ 4,037,599 $ 1,685,932 $ 37,500 $ 2,314,167
Other Intangible Assets	Other Intangible Assets As of June 30, 2021 2020 Balance – Beginning of Year $ 4,109,129 $ 4,755,675 Amounts capitalized 313,705 117,522 Software or patents written off (534 ) — Amortization (384,701 ) (764,068 ) Balance – End of Year $ 4,037,599 $ 4,109,129

NOTE 10 _ CONTROLLING AND NON_2

NOTE 10 – CONTROLLING AND NONCONTROLLING INTERESTS (Tables)	12 Months Ended
	Jun. 30, 2021
Noncontrolling Interest [Abstract]
Class A And B Members' Equity (HDM Acquisition)	Class A And B Members' Equity (HDM Acquisition) June 30, 2021 June 30, 2020 Class A Members Class B Member Class A Members Class B Member Opening Members’ Equity $ 55,253 $ 39,850,419 $ 2,155,725 $ 36,543,786 Share of Net Income 3,466,223 17,402,961 3,464,528 16,291,633 Distributions (6,570,000 ) (15,330,000 ) (5,565,000 ) (12,985,000 ) Ending Members’ Equity $ (3,048,524 ) $ 41,923,380 $ 55,253 $ 39,850,419

NOTE 11 - LONG-TERM DEBT, NOT_2

NOTE 11 - LONG-TERM DEBT, NOTES PAYABLE AND CAPITAL LEASES (Tables)	12 Months Ended
	Jun. 30, 2021
Leases [Abstract]
Long-term debt, notes payable and capital leases	Long-term debt, notes payable and capital leases 2021 2020 Note payable requiring monthly payments of interest at a rate of 7 % until May 2009 followed by 240 monthly payments of $ 4,472 through October 2026 . The loan is collateralized by a building with a net book value of $ 413,330 as of June 30, 2021. $ 232,696 $ 273,031 Note payable received under the Paycheck Protection Program (‘PPP’) which was established as part of the Coronavirus Aid, Relief and Economic Security Act (“Cares Act’) that provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses. The loans and accrued interest are forgivable after 24 weeks as long as the proceeds are used for eligible purposes, including payroll, benefits, rent and utilities and maintains certain payroll levels. The unforgiven portion of the PPP loan is payable over 5 five years at an interest rate of 1 %, with a deferral of payments for the first six months. The proceeds from the note payable were received on June 30, 2020. This note was forgiven in August 2021. 700,764 700,764 The revolving credit note was extended to August 2021. The Company can borrow up to $ 10,000,000 and prepay the loan in whole or part in multiples of $100,000 at any time without penalty. The note bears interest at a rate of 4.0 % per annum and is payable monthly. The loan is collateralized by substantially all of the Company’s assets. The loan also contains certain financial covenants that must be met on a periodic basis. The Company still has the ability to draw down on the line. See Note 21. — — 933,460 973,795 Less: Current portion 173,206 108,379 $ 760,254 $ 865,416
Maturities Of Long-Term Debt	Maturities Of Long-Term Debt Years Ending June 30, 2022 $ 173,206 2023 180,972 2024 183,919 2025 187,155 2026 190,601 Thereafter 17,607 Long-Term Debt Over Five Years and Thereafter $ 933,460

NOTE 12 - INCOME TAXES (Tables)

NOTE 12 - INCOME TAXES (Tables)	12 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Components Of The Benefit Provision For Income Taxes	Components Of The Benefit Provision For Income Taxes Years Ended June 30 Current: 2021 2020 Federal $ $ (187,255 ) State 1,136,514 513,204 Subtotal 1,136,514 325,949 Deferred: Federal deferred taxes 2,718,046 1,953,349 State deferred taxes 136,960 165,480 Subtotal 2,855,006 2,118,829 Provision (Benefit) for Income Taxes - Net $ 3,991,520 $ 2,444,778
Reconciliation Of Federal Statutory Income Tax Rate To Company's Effective Tax Rate	Reconciliation Of Federal Statutory Income Tax Rate To Company's Effective Tax Rate Years Ended June 30, 2021 2020 Taxes at federal statutory rate 21.0 % 21.0 % State and local income taxes (benefit), net of federal benefit 3.3 % 4.0 % Non Controlling interest (4.9 )% (6.1 )% Expiration of tax credits 4.6 % 0.2 % Return to provision adjustments 6.1 % — % Change in the valuation allowance (20.0 )% 0.3 % Other 12.5 % (2.1 )% Effective income tax rate 22.6 % 17.3 %
Components Of Company's Deferred Tax Assets And Liabilities	Components Of Company's Deferred Tax Assets And Liabilities June 30, 2021 2020 Deferred tax assets: Allowance for doubtful accounts $ 3,827,382 $ 3,946,801 Non-deductible accruals 749,902 693,833 Net operating carryforwards 8,285,163 13,720,637 Tax credits 3,732,650 4,647,217 Inventory 66,316 69,940 Property and equipment and depreciation 187,632 168,371 Deferred Tax Assets - gross 16,849,045 23,246,799 Valuation allowance (890,084 ) (4,437,042 ) Total deferred tax assets 15,958,961 18,809,757 Intangibles (238,316 ) (234,106 ) Total deferred tax liabilities (238,316 ) (234,106 ) Net deferred tax asset $ 15,720,645 $ 18,575,651

NOTE 13 - OTHER CURRENT LIABI_2

NOTE 13 - OTHER CURRENT LIABILITIES (Tables)	12 Months Ended
	Jun. 30, 2021
Payables and Accruals [Abstract]
Other Current Liabilities	Other Current Liabilities June 30, 2021 2020 Accrued salaries, commissions and payroll taxes $ 5,406,982 $ 4,491,941 Litigation accruals 900,000 442,802 Sales tax payable 644,623 1,353,200 State income taxes payable 774,234 — Legal and other professional fees 37,827 112,867 Accounting fees 127,262 120,000 Self-funded health insurance reserve 62,548 86,504 Accrued interest and penalty 493,042 877,787 Other 715,600 699,997 Other current liabilities $ 9,162,118 $ 8,185,098

NOTE 17 - SEGMENT AND RELATED_2

NOTE 17 - SEGMENT AND RELATED INFORMATION (Tables)	12 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
Summarized Segment Financial Information	Summarized Segment Financial Information Manufacturing and Servicing of Medical Management of Diagnostic Imaging Fiscal 2021: Equipment Center Totals Net revenues from external customers $ 9,037,091 $ 80,892,674 $ 89,929,765 Intersegment net revenues * $ 901,250 $ — $ 901,250 (Loss) Income from operations $ (3,410,189 ) $ 20,507,804 $ 17,097,615 Depreciation and amortization $ 264,830 $ 3,816,857 $ 4,081,687 Compensatory element of stock issuances $ 83,277 $ — $ 83,277 Total identifiable assets $ 24,592,582 $ 164,913,613 $ 189,506,195 Capital expenditures $ 291,294 $ 3,405,502 $ 3,696,796 Fiscal 2020: Net revenues from external customers $ 8,463,103 $ 77,227,359 $ 85,690,462 Intersegment net revenues * $ 875,000 $ — $ 875,000 (Loss) Income from operations $ (6,425,411 ) $ 20,076,327 $ 13,650,916 Depreciation and amortization $ 368,498 $ 3,540,150 $ 3,908,648 Compensatory element of stock issuances $ — $ — $ — Total identifiable assets $ 30,492,757 $ 149,790,753 $ 180,283,510 Capital expenditures $ 2,440,640 $ 4,981,773 $ 7,422,413 * Amounts eliminated in consolidation
Export Product Sales	Export Product Sales For the Years Ended June 30 2021 2020 Dominican Republic 67.0 % — % Canada 0.1 — Germany 2.1 20.2 Puerto Rico 0.1 — 69.3 % 20.2 %
Foreign Service and Repair Fees	Foreign Service and Repair Fees For the Years Ended June 30, 2021 2020 Puerto Rico 1.5 % 1.6 % Switzerland 0.3 0.3 Germany 1.5 1.5 England 0.6 0.7 Canada 0.3 0.3 Greece 0.3 0.2 Australia — 1.0 4.5 % 5.6 %

NOTE 18 _ ACQUISTION (Tables)

NOTE 18 – ACQUISTION (Tables)	12 Months Ended
	Jun. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Fair value assets and assumed liabilities	Fair value assets and assumed liabilities Property and equipment $ 650,000 Right to use assets 434,219 Intangible assets 150,000 Security Deposit 38,628 Right to use liability (434,219 ) Goodwill 283,880 Total purchase consideration $ 1,122,508
Net assets acquired	Net assets acquired Leasehold Improvements $ 550,000 Diagnostic Equipment 100,000 Customer Lists 100,000 Covenant Not to Compete 50,000 Security Deposit 38,628 Closing costs - expensed 3,478 Goodwill 283,880 Cash Consideration Paid $ 1,125,986

NOTE 19 _ ALLOWANCE FOR DOUBT_2

NOTE 19 – ALLOWANCE FOR DOUBTFUL ACCOUNTS (Tables)	12 Months Ended
	Jun. 30, 2021
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Summary of Allowance For Doubtful Accounts	Summary of Allowance For Doubtful Accounts Description Balance Additions (1) Deductions Balance Accounts receivable $ 514,561 $ — $ 72,291 $ 442,270 Management and other fees receivable 11,063,233 4,723,645 — 15,786,878 Management and other fees receivable - related medical practices 3,322,055 862,344 — 4,184,399 Notes receivable 777,354 — — 777,354 Balance Balance Description June 30, 2019 Additions Deductions June 30, 2020 Accounts receivable $ 190,244 $ 380,000 $ 55,683 $ 514,561 Management and other fees receivable 9,404,944 3,526,742 (1,868,453 ) 11,063,233 Management and other fees receivable - related medical practices 2,310,731 1,011,324 — 3,322,055 Notes receivable — 777,354 — 777,354 (1) Included in provision for bad debts.

NOTE 20 - QUARTERLY FINANCIAL_2

NOTE 20 - QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)	12 Months Ended
	Jun. 30, 2021
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data	Quarterly Financial Data September 30, 2020 December 30, 2020 March 31, 2021 June 30, 2021 Total Total Revenues – Net $ 20,979 $ 21,164 $ 23,090 $ 24,697 $ 89,930 Total Costs and Expenses 16,829 16,182 18,968 20,853 72,832 Net Income 3,251 3,928 4,299 2,196 13,674 Basic Net Income Per Common Share Available to Common Stockholders $ 0.37 $ 0.45 $ 0.55 $ 0.10 $ 1.47 Diluted Net Income Per Common Share Available to Common Stockholders $ 0.36 $ 0.44 $ 0.54 $ 0.11 $ 1.45 September 30, 2019 December 30, 2019 March 31, 2020 June 30, 2020 Total Total Revenues – Net $ 21,747 $ 21,451 $ 21,686 $ 20,806 $ 85,690 Total Costs and Expenses 16,261 16,430 19,071 20,278 72,040 Net Income 4,506 4,209 1,914 1,076 11,705 Basic Net Income Per Common Share Available to Common Stockholders $ 0.48 $ 0.45 $ 0.18 $ 0.09 $ 1.20 Diluted Net Income Per Common Share Available to Common Stockholders $ 0.47 $ 0.44 $ 0.18 $ 0.09 $ 1.18

NOTE 1 - DESCRIPTION OF BUSIN_2

NOTE 1 - DESCRIPTION OF BUSINESS AND LIQUIDITY AND CAPITAL RESOURCES (Details Narrative) - H D M [Member]	Jul. 01, 2015
[custom:ImperialContributionPercentage-0]	24.20%
Noncontrolling Interest, Ownership Percentage by Parent	45.80%
Investor [Member]
Noncontrolling Interest, Ownership Percentage by Parent	30.00%

NOTE 2 - SUMMARY OF SIGNIFICA_4

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Useful Life in Years - (Details)	12 Months Ended
	Jun. 30, 2021
Diagnostic Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Diagnostic Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	13 years
Research Deveopment And Demonstration Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Research Deveopment And Demonstration Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	2 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	9 years
Leasehold Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Leasehold Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Building [Member] | Weighted Average [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	28 years

NOTE 2 - SUMMARY OF SIGNIFICA_5

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Fee Revenue Recognition - (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Net Patient Fee Revenue	$ 23,307,389	$ 22,495,260
Commercial Insurance Managed Care [Member]
Net Patient Fee Revenue	4,100,440	4,545,987
Medicare Medicaid [Member]
Net Patient Fee Revenue	968,055	1,038,288
Workers Compensation Personal Injury [Member]
Net Patient Fee Revenue	15,011,111	16,028,737
Other Revenue Source [Member]
Net Patient Fee Revenue	$ 3,227,783	$ 882,248

NOTE 2 - SUMMARY OF SIGNIFICA_6

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share - (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Basic Numerator: Net Income Available to Common Stockholders	$ 10,207,588	$ 8,240,205
Basic Denominator: Weighted Average Shares Outstanding	6,505,283	6,443,713
Basic Income Per Common Share	$ 1.57	$ 1.28
Common Stock [Member]
Basic Numerator: Net Income Available to Common Stockholders	$ 9,592,134	$ 7,735,650
Basic Denominator: Weighted Average Shares Outstanding	6,505,283	6,443,713
Basic Income Per Common Share	$ 1.47	$ 1.20
Weighted average shares outstanding	6,505,283	6,443,713
Shares included upon conversion of Class C Common to calculate a diluted EPS	127,504	127,504
Total Denominator for Diluted Earnings Per Share	6,632,787	6,571,217
Diluted Income per Common Share	$ 1.45	$ 1.18
Common Class C [Member]
Basic Numerator: Net Income Available to Common Stockholders	$ 156,744	$ 128,500
Basic Denominator: Weighted Average Shares Outstanding	382,513	382,513
Basic Income Per Common Share	$ 0.41	$ 0.34
Weighted average shares outstanding	382,513	382,513
Shares included upon conversion of Class C Common to calculate a diluted EPS
Total Denominator for Diluted Earnings Per Share	382,513	382,513
Diluted Income per Common Share	$ 0.41	$ 0.34

NOTE 2 - SUMMARY OF SIGNIFICA_7

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	12 Months Ended
	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)shares
Product Information [Line Items]
Cost of Property Repairs and Maintenance	$ 2,051,000	$ 1,870,000
[custom:ManagementAgreementsWithCompanyTotalMedicalPractices-0]	22
[custom:ScannersWithManagementAgreementsWithCompanyOwnedByRelatedParty-0]	3
[custom:ScannersWithManagementWithCompanyLocatedInNewYorkState-0]	19
Advertising Expense	$ 633,000	566,000
[custom:ShippingAndHandlingExpense]	8,215	$ 12,056
[custom:NumberOfSharesUponConversionOfClassCCommonIncludedInDilutedEpsForCommonShareholders] | shares		127,504
Cash	42,609,000
Cash, FDIC Insured Amount	$ 250,000
Revenue Benchmark [Member]
Product Information [Line Items]
Concentration Risk, Percentage	12.00%	12.00%
Net Management Fee Receivables From Related Party Medical Practices [Member]
Product Information [Line Items]
Concentration Risk, Percentage	13.00%	13.00%
Diagnostic Imaging Facility [Member]
Product Information [Line Items]
[custom:ContractualFeesForServicesRenderedMinimum-0]	$ 77,000
[custom:ContractualFeesForServicesRenderedMaximum-0]	$ 522,000
Intellectual Property [Member]
Product Information [Line Items]
Finite-Lived Intangible Asset, Useful Life	15 years
Noncompete Agreements [Member]
Product Information [Line Items]
Finite-Lived Intangible Asset, Useful Life	7 years
Customer Relationships [Member]
Product Information [Line Items]
Finite-Lived Intangible Asset, Useful Life	20 years

NOTE 3 - ACCOUNTS RECEIVABLE, M

NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details)	Jun. 30, 2021USD ($)
Receivables [Abstract]
2023	$ 1,020,140
2024	1,020,140
2025	599,545
2026	160,697
Total	$ 2,800,522

NOTE 3 - ACCOUNTS RECEIVABLE,_2

NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Total Facilities (Details) - Integer	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Receivables [Abstract]
Total Facilities Owned or Managed (at Beginning of Year)	25	26
Acquisition	1
Internal development	1
Managed Facilities Closed		(1)
Total Facilities Owned or Managed (at End of Year)	27	25

NOTE 3 _ ACCOUNTS RECEIVABLE,_3

NOTE 3 – ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Details Narrative)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Receivables [Abstract]
[custom:PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims]	65.00%	66.00%
[custom:PercentageOfConsolidatedNetRevenueFromManagementFees]	12.00%	12.00%

NOTE 4 - CONTRACT ASSETS AND LI

NOTE 4 - CONTRACT ASSETS AND LIABILITIES - Costs, Earnings, Billings, Uncompleted Contracts - (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Regulated Operations [Abstract]
Costs incurred on uncompleted contracts	$ 294,783	$ 448,437
Estimated earnings	567,978	309,248
Costs and estimated earnings on uncompleted contracts	862,761	757,685
Less: Billings to date	877,500	604,852
Costs and estimated earnings in excess of billings on uncompleted contracts	$ (14,739)	$ 152,833

NOTE 5 - INVENTORIES - Inventor

NOTE 5 - INVENTORIES - Inventories (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Inventory Disclosure [Abstract]
Purchased parts, components and supplies	$ 1,393,329	$ 1,544,036
Work-in-process	270,090	104,734
Inventories	$ 1,663,419	$ 1,648,770

NOTE 6 - PROPERTY AND EQUIPME_3

NOTE 6 - PROPERTY AND EQUIPMENT - Property and Equipment (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Property, Plant and Equipment [Line Items]
Property and Equipment Before Accumulated depreciation and amortization	$ 55,277,600	$ 51,373,184
Less: Accumulated depreciation and amortization of property and equipment	33,427,461	30,009,150
Property and Equipment AfterAccumulated depreciation and amortization	21,850,139	21,364,034
Diagnostic Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment Before Accumulated depreciation and amortization	29,826,829	28,434,063
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment Before Accumulated depreciation and amortization	6,029,551	5,901,961
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment Before Accumulated depreciation and amortization	2,069,055	2,069,055
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment Before Accumulated depreciation and amortization	3,450,664	3,291,666
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment Before Accumulated depreciation and amortization	12,961,887	10,736,825
Building [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment Before Accumulated depreciation and amortization	$ 939,614	$ 939,614

NOTE 6 - PROPERTY AND EQUIPME_4

NOTE 6 - PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Property, Plant and Equipment [Member]
Property, Plant and Equipment [Line Items]
Cost, Depreciation and Amortization	$ 3,696,986	$ 3,144,580

NOTE 7 - OPERATING & FINANCING

NOTE 7 - OPERATING & FINANCING LEASES - Lease Payments (Details)	Jun. 30, 2021USD ($)
Note 7 Operating Financing Leases
2022	$ 5,077,656
2022	244,343
2023	5,172,157
2023	244,343
2024	4,837,900
2024	244,343
2025	4,725,550
2025	244,343
2026	4,285,124
2026	244,343
Thereafter	16,950,126
Thereafter	162,898
Present Value discount	(8,539,725)
Present Value discount, Financing Lease	(133,441)
Total lease liability	32,508,788
Total lease liability	$ 1,251,172
Operating Lease, Weighted Average Remaining Lease Term	9 years 4 months 24 days
Finance Lease, Weighted Average Remaining Lease Term	5 years 7 months 6 days
Operating Lease, Weighted Average Discount Rate, Percent	5.50%
Finance Lease, Weighted Average Discount Rate, Percent	3.60%

NOTE 7 - OPERATING & FINANCIN_2

NOTE 7 - OPERATING & FINANCING LEASES - Recent Accounting Pronouncements - Components of lease expense (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Note 7 Operating Financing Leases
Operating lease cost	$ 6,145,701	$ 5,135,604
Finance lease cost:
Depreciation of leased equipment	198,881
Interest on lease liabilities	47,472
Total finance lease cost	$ 246,353

NOTE 7 - OPERATING & FINANCIN_3

NOTE 7 - OPERATING & FINANCING LEASES - Recent Accounting Pronouncements - Related to leases (Details) - USD ($)		12 Months Ended
		Jun. 30, 2021	Jun. 30, 2020
Note 7 Operating Financing Leases
Operating cash flows from operating leases		$ 4,970,934	$ 4,170,977
Financing cash flows from financing leases		130,038
Operating leases(1)	[1]	1,531,889	34,786,611
Financing leases			$ 1,325,871
[1]	Amounts for the year ended June 30, 2020 include the transition adjustment for the adoption of topic 842 of $31,651,110.

NOTE 7 _ OPERATING & FINANCIN_3

NOTE 7 – OPERATING & FINANCING LEASES (Details Narrative)	12 Months Ended
	Jun. 30, 2021USD ($)
Note 7 Operating Financing Leases
Operating Lease, Payments	$ 33,300,000

NOTE 8 - OTHER INTANGIBLE ASS_3

NOTE 8 - OTHER INTANGIBLE ASSETS - Other Intagible Assets Net of Amoritization (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Finite-Lived Intangible Assets [Line Items]
Other intangible assets - gross	$ 20,299,739	$ 19,986,568
Less: Accumulated amortization	16,262,140	15,877,439
Other intangible assets - net	4,037,599	4,109,129	$ 4,755,675
Software and Software Development Costs [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangible assets - gross	7,004,847	7,004,847
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangible assets - gross	5,244,892	5,081,721
Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangible assets - gross	4,150,000	4,100,000
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangible assets - gross	$ 3,900,000	$ 3,800,000

NOTE 8 - OTHER INTANGIBLE ASS_4

NOTE 8 - OTHER INTANGIBLE ASSETS - Forward Looking Schedule of Other Intangible Assets - (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Finite-Lived Intangible Assets [Line Items]
2022	$ 423,209
2023	389,168
2024	388,867
2025	383,912
2026	373,220
Thereafter	2,079,223
Other intangible assets - net	4,037,599	$ 4,109,129
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
2022	185,709
2023	189,168
2024	188,867
2025	183,912
2026	173,220
Thereafter	765,056
Other intangible assets - net	1,685,932
Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
2022	37,500
2023
2024
2025
2026
Thereafter
Other intangible assets - net	37,500
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
2022	200,000
2023	200,000
2024	200,000
2025	200,000
2026	200,000
Thereafter	1,314,167
Other intangible assets - net	$ 2,314,167

NOTE 8 - OTHER INTANGIBLE ASS_5

NOTE 8 - OTHER INTANGIBLE ASSETS - Schedule Of Intangle Assets - (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Balance - End of Year	$ 4,109,129	$ 4,755,675
Amounts capitalized	313,705	117,522
Software or patents written off	(534)
Amortization	(384,701)	(764,068)
Balance - End of Year	$ 4,037,599	$ 4,109,129

NOTE 8 - OTHER INTANGIBLE ASS_6

NOTE 8 - OTHER INTANGIBLE ASSETS (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	11 years 4 months 24 days
Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 179,701	$ 183,592
Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	12,500	390,476
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 192,500	$ 190,000

NOTE 9 - CAPITAL STOCK (Details

NOTE 9 - CAPITAL STOCK (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Aug. 10, 2010	Apr. 23, 2010
Other Selling, General and Administrative Expense	$ 83,277	$ 0
N 2010 Stock Bonus Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance				2,000,000
[custom:SharesRegistered-0]			2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	450,177
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	106,747	89,981
Common Stock [Member]
Dividends Payable, Nature	Cash dividends payable on the common stock shall, in all cases, be on a per share basis, one hundred twenty percent (120%) of the cash dividend payable on shares of Class B common stock and three hundred sixty percent (360%) of the cash dividend payable on a share of Class C common stock.
Stockholders' Equity Note, Impact of Conversion of Contingently Convertible Securities on Diluted Earnings Per Share	Class C common stock is convertible into shares of common stock on a three-for-one basis.
Common Stock, Voting Rights	one vote per share for the common stock.
Common Stock, Shares, Outstanding	6,554,210	6,447,463
Common Class B [Member]
Stockholders' Equity Note, Impact of Conversion of Contingently Convertible Securities on Diluted Earnings Per Share	Class B common stock is convertible into shares of common stock on a one-for-one basis.
Common Stock, Voting Rights	Class B common stock has 10 votes per share
Common Stock, Shares, Outstanding		146
Common Class C [Member]
Dividends Payable, Nature	Although having greater voting power, each share of Class C common stock has only one-third of the rights of a share of Class B common stock to dividends and distributions.
Stockholders' Equity Note, Impact of Conversion of Contingently Convertible Securities on Diluted Earnings Per Share	The Class C common stock was offered on a three-for-one basis to the holders of the Class B common stock.
Common Stock, Voting Rights	The Class C common stock has 25 votes per share
Common Stock, Shares, Outstanding		382,513
Preferred Class A [Member]
Dividends Payable, Nature	The stock dividend was payable to holders of common stock on October 20, 1995. Class A non-voting preferred stock issued pursuant to such stock dividend approximates 313,000 shares.
Common Stock, Voting Rights	one share of Class A non-voting preferred stock for every five shares of common stock.

NOTE 10 - CONTROLLING AND NONCO

NOTE 10 - CONTROLLING AND NONCONTROLLING INTERESTS - HDM Members Equity (Details) - H D M Equity [Member] - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Common Class A [Member]
Noncontrolling Interest [Line Items]
Opening Members Equity	$ 55,253	$ 2,155,725
Share of Net Income	3,466,223	3,464,528
Distributions	(6,570,000)	(5,565,000)
Ending Members Equity	(3,048,524)	55,253
Common Class B [Member]
Noncontrolling Interest [Line Items]
Opening Members Equity	39,850,419	36,543,786
Share of Net Income	17,402,961	16,291,633
Distributions	(15,330,000)	(12,985,000)
Ending Members Equity	$ 41,923,380	$ 39,850,419

NOTE 10 _ CONTROLLING AND NON_3

NOTE 10 – CONTROLLING AND NONCONTROLLING INTERESTS (Details Narrative)	1 Months Ended
	Feb. 13, 2013USD ($)	Jan. 08, 2015USD ($)	Mar. 05, 2013USD ($)Integer
H D M [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
[custom:PurchaseOfStandupMriCenters-0] | Integer			12
[custom:PurchaseOfOtherMriCenters-0] | Integer			2
[custom:ConsiderationToOutsideInvestors-0]			$ 1,500,000
[custom:TotalPurchasePrice-0]			35,900,000
[custom:ConsiderationForNoncompetitionAndConsultingAgreements-0]			$ 4,100,000
H D M [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Proceeds from Contributions from Affiliates	$ 20,200,000
H D M [Member] | Outside Investors [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Proceeds from Contributions from Affiliates	$ 19,800,000
Class B [Member] | H D M Equity [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	50.50%
[custom:OwnershipPercentageAcquired-0]	50.50%
Class A [Member] | H D M [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	49.50%	60.40%
Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value		$ 4,971,094

NOTE 11 - LONG-TERM DEBT, NOT_3

NOTE 11 - LONG-TERM DEBT, NOTES PAYABLE AND CAPITAL LEASES Long-Term Debt, Notes Payable And Capital Leases - (Details)	12 Months Ended
	Jun. 30, 2021USD ($)Integer	Jun. 30, 2020USD ($)
Debt Instrument [Line Items]
Long Term Debt, Notes Payable and Capital Leases	$ 933,460	$ 973,795
Current portion of Long Term Debt, Notes Payable and Capital Leases	173,206	108,379
Long Term Debt, Notes Payable and Capital Leases less Current Portion	$ 760,254	865,416
Note Payable 1 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period	7.00%
[custom:NumberOfInstallment] | Integer	240
Debt Instrument, Frequency of Periodic Payment	monthly
Debt Instrument, Periodic Payment	$ 4,472
[custom:MaturityDate]	October 2026
[custom:BookValueOfBuilding-0]	$ 413,330
Long Term Debt, Notes Payable and Capital Leases	$ 232,696	273,031
Note Payable 2 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period	1.00%
Long Term Debt, Notes Payable and Capital Leases	$ 700,764	700,764
Debt Instrument, Term	5 years
Note Payable 3 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period	4.00%
Long Term Debt, Notes Payable and Capital Leases
Proceeds from Lines of Credit	$ 10,000,000

NOTE 11 - LONG-TERM DEBT, NOT_4

NOTE 11 - LONG-TERM DEBT, NOTES PAYABLE & CAPITAL LEASES - Maturities Of Long-Term Debt Over 5 Years - (Details)	Jun. 30, 2020USD ($)
Leases [Abstract]
2022	$ 173,206
2023	180,972
2024	183,919
2025	187,155
2026	190,601
Thereafter	17,607
Long-Term Debt Over Five Years and Thereafter	$ 933,460

NOTE 12 - INCOME TAXES - Reconc

NOTE 12 - INCOME TAXES - Reconciliation of Federal Statutory Income Tax Rate (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Federal		$ (187,255)
State	$ 1,136,514	513,204
Subtotal	1,136,514	325,949
Federal deferred taxes	2,718,046	1,953,349
State deferred taxes	136,960	165,480
Subtotal	2,855,006	2,118,829
Provision (Benefit) for Income Taxes - Net	$ 3,991,520	$ 2,444,778

NOTE 12 - INCOME TAXES - Signif

NOTE 12 - INCOME TAXES - Significant Components Of Company's Deferred Tax Assets And Liabilities - (Details)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Taxes at federal statutory rate	21.00%	21.00%
State and local income taxes (benefit), net of federal benefit	3.30%	4.00%
Non Controlling interest	(4.90%)	(6.10%)
Expiration of tax credits	4.60%	0.20%
Return to provision adjustments	6.10%
Change in the valuation allowance	(20.00%)	0.30%
Other	12.50%	(2.10%)
Effective income tax rate	22.60%	17.30%

NOTE 12 - INCOME TAXES - Compon

NOTE 12 - INCOME TAXES - Components Of Company's Deferred Tax Assets And Liabilities - (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Deferred tax assets:
Allowance for doubtful accounts	$ 3,827,382	$ 3,946,801
Non-deductible accruals	749,902	693,833
Net operating carryforwards	8,285,163	13,720,637
Tax credits	3,732,650	4,647,217
Inventory	66,316	69,940
Property and equipment and depreciation	187,632	168,371
Deferred Tax Assets - gross	16,849,045	23,246,799
Valuation allowance	(890,084)	(4,437,042)
Total deferred tax assets	15,958,961	18,809,757
Intangibles	(238,316)	(234,106)
Total deferred tax liabilities	(238,316)	(234,106)
Net deferred tax asset	$ 15,720,645	$ 18,575,651

NOTE 12 - INCOME TAXES (Details

NOTE 12 - INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Deferred Tax Assets, Net of Valuation Allowance	$ 15,958,961	$ 18,809,757
Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Policyholders' Surplus	238,316
Operating Loss Carryforwards	35,574,000
Operating Income (Loss)	7,094,000
Other Operating Income	2,470,000
Deferred Taxes, Business Combination, Valuation Allowance, Allocated to Contributed Capital	$ 3,547,000	$ 195,000
[custom:ReimbursementOfAlternativeMinimumTaxCreditsDescription]	Company is allowing a full reimbursement of $1,342,370 of tax credits relating to the alternative minimum tax credits. The Company received the first half payment in June 2020. The balance of alternative minimum tax credits of $671,185 was received in July 2020. Previously, these credits were to be refunded over a 3 year period.
Deferred Tax Assets, Tax Credit Carryforwards, Research	$ 3,733,000
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount	890,000
Tax Credit Carryforward, Amount	11,000
[custom:AdditionalTaxes]	$ 423,272

NOTE 13 - OTHER CURRENT LIABI_3

NOTE 13 - OTHER CURRENT LIABILITIES - Other Current Liabilities - (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Payables and Accruals [Abstract]
Accrued salaries, commissions and payroll taxes	$ 5,406,982	$ 4,491,941
Litigation accruals	900,000	442,802
Sales tax payable	644,623	1,353,200
State income taxes payable	774,234
Legal and other professional fees	37,827	112,867
Accounting fees	127,262	120,000
Self-funded health insurance reserve	62,548	86,504
Accrued interest and penalty	493,042	877,787
Other	715,600	699,997
Other current liabilities	$ 9,162,118	$ 8,185,098

NOTE 14 - COMMITMENTS AND CON_2

NOTE 14 - COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	12 Months Ended		120 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2028
Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]
Operating Leases, Rent Expense	$ 6,146,000	$ 5,136,000
[custom:PropertyTaxAbatementFromSuffolkCountyIda]			50.00%
[custom:PropertyTaxAbatement]			$ 440,000
Employee Stock Ownership Plan (ESOP), Cash Contributions to ESOP	$ 36,799	$ 0
[custom:LitigationSettelementDescription]	In September 2020, the Company entered into a settlement agreement with an unrelated third party for a claim made during March 2018 which was scheduled for arbitration. The settlement was for $1.2 million of which $900,000 was paid by the Company’s insurance on September 15, 2020 with the remaining $315,000 paid by the Company on September 28, 2020.	In September 2019, The Company was notified by one of its landlords that it was required to vacate the premises within 180 days under the demolition clause in the lease. The Company believes the lease renewal which was not negotiated in good faith since the renewal was negotiated in February 2018. The Company is in the process of relocating to a new location but the original lease provided for penalty payments in the event that the Company had not vacated the leased space. The Company has been making normal rent payments throughout the course of the arbitration proceedings. The Company is estimating the leasehold holdover charges to be approximately $900,000.
Sales and Excise Tax Payable	$ 645,000
[custom:RecordedSalesTaxObligationsInterestAndPenalties-0]	232,000
[custom:StoplossUmbrellaPolicyWith3RdParyinsurerToLimitMaximumPotentialLiabilityForIndividualClaims]	110,000
Liability for Claims and Claims Adjustment Expense, Disability, Accident and Health	$ 63,000	$ 87,000
Employee Stock [Member]
Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]
[custom:EmployeeStockPurchasePlanEspp]	The stockholders of the Company approved the 2000 Employee Stock Purchase Plan (“ESPP”) at the Company’s annual stockholders’ meeting in April 2000. The ESPP provides for eligible employees to acquire common stock of the Company at a discount, not to exceed 15%. This plan has not been put into effect as of June 30, 2021.

NOTE 15 - SUPPLEMENTAL CASH F_2

NOTE 15 - SUPPLEMENTAL CASH FLOW INFORMATION (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Supplemental Cash Flow Elements [Abstract]
Interest Paid, Including Capitalized Interest, Operating and Investing Activities	$ 75,178	$ 137,200
Income Taxes Paid	$ 261,032	$ 228,204
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture	102,364	89,981
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	$ 1,940,821	$ 1,990,380
Amortization of Leased Asset	1,350,000
[custom:SellingGeneralAndAdministrativeExpenses]	$ 602,000

NOTE 16 _ RELATED PARTY TRANS_2

NOTE 16 – RELATED PARTY TRANSACTIONS (Details Narrative)	12 Months Ended
	Jun. 30, 2021
A Billing Company [Member]
Related Party Transaction, Description of Transaction	The CEO and President of the Company is a minority owner of a billing company, which performs billing and collection services with respect to No-Fault and Workers’ Compensation claims of the Company’s clients. The monthly fee charged to the Company was $85,000. The Company terminated this agreement on January 1, 2021. On June 1, 2017, the Company also entered into a one year renewable agreement to provide IT services to the billing company for a monthly fee of $23,884. The agreement was renewed on June 1, 2021 for another year.
Bensonhurst M R I Limited Partnership [Member]
Related Party Transaction, Description of Transaction	Bensonhurst MRI Limited Partnership, in which the CEO and President of the Company holds an interest, is party to an agreement with the Company for the service and maintenance of its Upright MRI Scanner for a price of $110,000 per annum.

NOTE 17 - SEGMENT AND RELATED_3

NOTE 17 - SEGMENT AND RELATED INFORMATION - Sumarized Segments - (Details) - USD ($)		12 Months Ended
		Jun. 30, 2021	Jun. 30, 2020
Total Revenues - Net		$ 89,929,765	$ 85,690,462
Intersegment net revenues	[1]	901,250	875,000
(Loss) Income from operations		17,097,615	13,650,916
Depreciation and amortization		4,081,687	3,908,648
Compensatory element of stock issuances		83,277	0
Total identifiable assets		189,506,195	180,283,510
Capital expenditures		3,696,796	7,422,413
Manufacturing And Servicing Of Medical Equipment [Member]
Total Revenues - Net		9,037,091	8,463,103
Intersegment net revenues	[1]	901,250	875,000
(Loss) Income from operations		(3,410,189)	(6,425,411)
Depreciation and amortization		264,830	368,498
Compensatory element of stock issuances		83,277
Total identifiable assets		24,592,582	30,492,757
Capital expenditures		291,294	2,440,640
Management Of Diagnostic Imaging Centers [Member]
Total Revenues - Net		80,892,674	77,227,359
Intersegment net revenues	[1]
(Loss) Income from operations		20,507,804	20,076,327
Depreciation and amortization		3,816,857	3,540,150
Compensatory element of stock issuances
Total identifiable assets		164,913,613	149,790,753
Capital expenditures		$ 3,405,502	$ 4,981,773
[1]	Amounts eliminated in consolidation

NOTE 17 - SEGMENT AND RELATED_4

NOTE 17 - SEGMENT AND RELATED INFORMATION - Foreign Product Sales - (Details)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
[custom:ForeignProductSales]	69.30%	20.20%
DOMINICAN REPUBLIC
Revenues from External Customers and Long-Lived Assets [Line Items]
[custom:ForeignProductSales]	67.00%	0.00%
CANADA
Revenues from External Customers and Long-Lived Assets [Line Items]
[custom:ForeignProductSales]	0.10%	0.00%
GERMANY
Revenues from External Customers and Long-Lived Assets [Line Items]
[custom:ForeignProductSales]	2.10%	20.20%
PUERTO RICO
Revenues from External Customers and Long-Lived Assets [Line Items]
[custom:ForeignProductSales]	0.10%	0.00%

NOTE 17 - SEGMENT AND RELATED_5

NOTE 17 - SEGMENT AND RELATED INFORMATION - Foreign Service and Repair Fees - (Details)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Foreign Service and Repair fees	4.50%	5.60%
PUERTO RICO
Revenues from External Customers and Long-Lived Assets [Line Items]
Foreign Service and Repair fees	1.50%	1.60%
SWITZERLAND
Revenues from External Customers and Long-Lived Assets [Line Items]
Foreign Service and Repair fees	0.30%	0.30%
GERMANY
Revenues from External Customers and Long-Lived Assets [Line Items]
Foreign Service and Repair fees	1.50%	1.50%
UNITED KINGDOM
Revenues from External Customers and Long-Lived Assets [Line Items]
Foreign Service and Repair fees	0.60%	0.70%
CANADA
Revenues from External Customers and Long-Lived Assets [Line Items]
Foreign Service and Repair fees	0.30%	0.30%
GREECE
Revenues from External Customers and Long-Lived Assets [Line Items]
Foreign Service and Repair fees	0.30%	0.20%
AUSTRALIA
Revenues from External Customers and Long-Lived Assets [Line Items]
Foreign Service and Repair fees	0.00%	1.00%

NOTE 17 - SEGMENT AND RELATED_6

NOTE 17 - SEGMENT AND RELATED INFORMATION (Details Narrative)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Segment Reporting [Abstract]
[custom:ExportSalesOfMedicalEquipmentPercentage]	69.30%	20.20%
[custom:ForeignRevenuesOfServiceAndRepairOfMedicalEquipmentPercentage]	4.50%	5.60%

NOTE 18 - ACQUISTION - Fair val

NOTE 18 - ACQUISTION - Fair value assets and assumed liabilities (Details) - USD ($)	Jun. 30, 2021	Mar. 29, 2021	Jun. 30, 2020
Business Combination and Asset Acquisition [Abstract]
Property and equipment		$ 650,000
Right to use assets		434,219
Intangible assets		150,000
Security Deposit		38,628
Right to use liability		(434,219)
Goodwill	$ 4,269,277	283,880	$ 3,985,397
Total purchase consideration		$ 1,122,508

NOTE 18 - ACQUISTION - Net asse

NOTE 18 - ACQUISTION - Net assets acquired (Details)	Mar. 29, 2021USD ($)
Business Acquisition [Line Items]
Intangible assets	$ 150,000
Security Deposit	38,628
Closing costs - expensed	3,478
Goodwill	283,880
Cash Consideration Paid	1,125,986
Rockland Management Group [Member] | Leasehold Improvements [Member]
Business Acquisition [Line Items]
Intangible assets	550,000
Rockland Management Group [Member] | Diagnostic Equipment [Member]
Business Acquisition [Line Items]
Intangible assets	100,000
Rockland Management Group [Member] | Customer Lists [Member]
Business Acquisition [Line Items]
Intangible assets	100,000
Rockland Management Group [Member] | Covenant Not To Compete [Member]
Business Acquisition [Line Items]
Intangible assets	$ 50,000

NOTE 19 - ALLOWANCE FOR DOUBTFU

NOTE 19 - ALLOWANCE FOR DOUBTFUL ACCOUNTS - Allowance For Doubtful Accounts (Details) (USD $) - USD ($)		12 Months Ended
		Jun. 30, 2021		Jun. 30, 2020
Accounts Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Beginning Balance		$ 514,561		$ 190,244
Additions (Included in provision for bad debts)			[1]	380,000
Deductions		72,291		55,683
Ending Balance		442,270		514,561
Management And Other Fees Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Beginning Balance		11,063,233		9,404,944
Additions (Included in provision for bad debts)		4,723,645	[1]	3,526,742
Deductions				(1,868,453)
Ending Balance		15,786,878		11,063,233
Management And Other Fees Receivable Related Medical Practices [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Beginning Balance		3,322,055		2,310,731
Additions (Included in provision for bad debts)		862,344	[1]	1,011,324
Deductions
Ending Balance		4,184,399		3,322,055
Notes Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Beginning Balance		777,354
Additions (Included in provision for bad debts)	[1]
Deductions
Ending Balance		777,354		777,354
Medical Receivables [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Beginning Balance		$ 777,354
Additions (Included in provision for bad debts)				777,354
Deductions
Ending Balance				$ 777,354
[1]	Included in provision for bad debts.

NOTE 20 - QUARTERLY FINANCIAL_3

NOTE 20 - QUARTERLY FINANCIAL DATA (UNAUDITED) - Unaudited Quarterly Financial Tables- (Details) - USD ($)	3 Months Ended								12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2021	Jun. 30, 2020
Total Revenues – Net									$ 89,929,765	$ 85,690,462
Total Costs and Expenses									72,832,150	72,039,546
Net Income									13,673,811	11,704,733
Quarterly Financial Data [Member]
Total Revenues – Net	$ 24,697	$ 23,090	$ 21,164	$ 20,979	$ 20,806	$ 21,686	$ 21,451	$ 21,747	89,930	85,690
Total Costs and Expenses	20,853	18,968	16,182	16,829	20,278	19,071	16,430	16,261	72,832	72,040
Net Income	$ 2,196	$ 4,299	$ 3,928	$ 3,251	$ 1,076	$ 1,914	$ 4,209	$ 4,506	$ 13,674	$ 11,705
Basic Net Income Per Common Share Available to Common Stockholders	$ 0.10	$ 0.55	$ 0.45	$ 0.37	$ 0.09	$ 0.18	$ 0.45	$ 0.48	$ 1.47	$ 1.20
Diluted Net Income Per Common Share Available to Common Stockholders	$ 0.11	$ 0.54	$ 0.44	$ 0.36	$ 0.09	$ 0.18	$ 0.44	$ 0.47	$ 1.45	$ 1.18

NOTE 21 _ SUBSEQUENT EVENTS (De

NOTE 21 – SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member]	1 Months Ended
	Aug. 31, 2021USD ($)
Subsequent Event [Line Items]
Debtor-in-Possession Financing, Fee on Unused Borrowings	4.00%
Proceeds from Loans	$ 700,764